MEMBERS OF THE EXECUTIVE COMMITTEE

<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>C G Eden</td>
<td>D A Gillatt</td>
<td>D R Greene</td>
<td>D C Hanbury</td>
</tr>
<tr>
<td>R C Kocklebergh</td>
<td>G S McIntosh</td>
<td>J K Mellon</td>
<td>R A Persad</td>
</tr>
<tr>
<td>R D Pocock</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PRODUCED FOR BAUS SECTION OF ONCOLOGY

by

Mrs Sarah Fowler
BAUS Cancer Registry Manager
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>Results Summary &amp; Methods of analysis</td>
<td>3</td>
</tr>
<tr>
<td>A. Participants and Overall Figures</td>
<td>4</td>
</tr>
<tr>
<td>Charts 1 – 25</td>
<td></td>
</tr>
<tr>
<td>B. Referral Source, Priority &amp; Time between Referral, First Consultation, Diagnosis and Definitive Treatment</td>
<td>18</td>
</tr>
<tr>
<td>Charts 26 – 60</td>
<td></td>
</tr>
<tr>
<td>C. Histology</td>
<td>37</td>
</tr>
<tr>
<td>Charts 61 – 65</td>
<td></td>
</tr>
<tr>
<td>D. Staging</td>
<td>40</td>
</tr>
<tr>
<td>Charts 66 – 78</td>
<td></td>
</tr>
<tr>
<td>E. Initial Treatment Intention &amp; Type</td>
<td>47</td>
</tr>
<tr>
<td>Charts 79 – 92</td>
<td></td>
</tr>
<tr>
<td>F. Tertiary Referrals</td>
<td>55</td>
</tr>
<tr>
<td>Chart 93</td>
<td></td>
</tr>
<tr>
<td>G. Clinical Trial Status / Delay to Diagnosis &amp; Discussion at MDT meeting</td>
<td>56</td>
</tr>
<tr>
<td>Charts 94 – 96</td>
<td></td>
</tr>
<tr>
<td>H. Completeness of Data</td>
<td>58</td>
</tr>
<tr>
<td>Charts 97 – 98</td>
<td></td>
</tr>
<tr>
<td>Appendix – Participating Hospitals over the Years 1998-2004</td>
<td>59</td>
</tr>
</tbody>
</table>
INTRODUCTION

It is a pleasure to write the introduction to the analysis of new urological cancers for 2004 and to present it on behalf of the Executive Committee of the Oncology Section.

As will be seen the number of returns in 2004 has fallen for the second successive year (24,532 new cancers this year with 27,225 in 2003) and regrettably the number of participating centres and individuals this year has also declined. Nineteen centres have not sent in any data after July 2004 – they are listed as participants but only for half the year. Ninety-two surgeons did not enter data for 2004, having done so in 2003, but seventy-four new entrants sent in data having not done so before. We can speculate as to the reasons for these reductions – some may be due to the impact of centralisation of urological cancer services either directly with fewer trusts or hospitals providing major cancer services or indirectly with lack of enthusiasm to continue to collect data by individuals or trusts when they are no longer permitted to carry out complex operations. It is a shame that the initial enthusiasm and commitment of the BAUS Oncology Section membership for data capture and entry appears to have been lost. Perhaps naively in 1997/8 many urologists believed that if they demonstrated how many new patients with cancer they were detecting and treating, that this would be recognised and their contribution valued by being allowed to continue such work. For the first time we have included a list of participating hospitals and have indicated the years for which data has been contributed and whether data for the complex operations audit was submitted. Study of this list will show some major centres contributing little or no data to both databases! A full list of participating consultants over the years is available from a member’s only section of the BAUS web-site.

There is significant variation in the number of returns of new cancers for different parts of the UK and whereas in the past the analyses for England have been on a regional basis, we have for the first time this year carried out an analysis by cancer networks. As is shown in Chart 11 there is one network which returned no data at all whilst one of the smallest networks with a population of only 700,000 approximately has the highest return rate. This can be interpreted as enthusiasm and organisation by individuals or organisations for data capture versus apathy or lack of resource to allow data collection and entry. Unfortunately returns from Scotland have fallen dramatically for the second year. The cessation of the Scottish Urological Cancer Audit is the most obvious cause of this decline.

As ever, detailed study of the figures reveal interesting nuggets – for example the rapid change of the percentage of prostate cancers being diagnosed with impalpable disease (T1c) – 8.6% in 1998 to 21.5% in 2004. Also gratifying is the drop in the percentage of patients being diagnosed with metastatic prostate cancer – 14.9% in 1998 to 7.1% in 2004. There is much more such information within the analyses which will be the reward of detailed study.

The BCR minimum dataset database is an extremely valuable resource with over 150,000 new urological cancer patients registered and traceable. Insufficient use of the database for research and study is being made, and without such studies the database will become the electronic equivalent of a dusty unopened ledger on some library shelf. The Oncology Section is ever open to approaches to make use of the database for research and the committee look forward to receiving applications. Hopefully, with such studies and publication of the results there will be appreciation of the value of this resource.

Adequate secure funding of the database would allow data entry to be enhanced and validated and also enable greater analytical ability. Despite many attempts we have not been able to secure such funding. It is regrettable that other national databases (e.g. Lung cancer and Head and Neck Oncology) are centrally funded, whereas we are not. BAUS Council is to be approached on behalf of this and other sections to request funding and some finance has been promised from the pharmaceutical industry.
Audit of individuals or organisations work or caseload is an integral and vital part of clinical governance and with the minimum dataset and the complex operations audit part of the database we have an excellent available urological resource. With the clinical reorganisation of the Improving Outcome Guidance for Urological cancers it should become mandatory that cancer centres take part in comparative audit for their workload and outcomes. We are in place to allow this.

I trust that we can recapture the enthusiasm that prevailed when the Section of Oncology was formed eight years ago and that this will be reflected in a reverse of the decline in the returns of the last two years.

Gregor McIntosh
Consultant Urological Surgeon
Salisbury

October 2005
AUDIT RESULTS SUMMARY January 1st – 31st December 2004

Who took part?

423 consultant urologists from 140 hospital centres in England, Wales, Scotland and Northern Ireland provided data for this study submitting data on 24,532 newly presenting urological tumours from 1st January to 31st December 2004. Of the 423 consultants, 214 (51%) are members of the BAUS section of Oncology and returned 75% of the data. These figures represent approximately 48% of the total UK tumours registered in 2002/2003 (50,529) (the most recent years available).

3.5% (871/24532) were the private patients of 133 consultants.

How were the data analysed?

Information obtained from consultants was entered into the computer database using unique identifying numbers for individual consultants or, if they preferred, a centre number. Eight centres returned data under a centre number only (36 consultants in total) and data from two other centres was returned under the centre number only for 2 out of 7 and 4 out of 5 consultants.

Data could be returned either by completion of a pro forma for each patient (3,876 – 16% of returns) or in electronic format using either an Access (Microsoft) database or “in-house” database (20,883 – 84% of returns) designed for the purpose. The pro formas were entered directly into an Access database, at which time validation comprising mainly of checks for duplicate entries and on dates and sex of patient could be carried out. 97 tumours were registered twice as a tertiary referral from another centre or another consultant in the same centre. They were only included once in all the analyses using the data from the primary site for all analyses except those relating to staging and treatment when the tertiary site data was used. In addition 9 benign tumours were registered but these have been excluded from all analyses as were 8 tertiary referrals that had been registered at their primary site in previous years’ analyses.

The data presented here are a summary of the data received up to 19th September 2005 and relate to diagnoses made during the whole of 2004. The following data was included:

a. Patients for who the date of diagnosis fell within the time period. (01/01/2004 to 31/12/2004). 24,400 registrations (99.5%).

b. Patients for whom the date of diagnosis was either not included or the patient was a tertiary referral, but the referral date fell within the study period. (01/01/2004 to 31/12/2004) 107 registrations (0.4%).

c. Patients for whom the diagnosis and referral dates were either not included or the patient was a tertiary referral, but the date of first consultation fell within the study period. (01/01/2003 to 31/12/2003). 25 (0.1%).

For the ranked charts (2, 3, 5 & 6) the individual consultant or centre identification numbers were removed and replaced with rank numbers starting at 1. A unique, confidential "Ranking Sheet" was prepared for each surgeon to enable them to identify their rank in every chart. For those charts where overall figures for the entire database are shown the ranking sheet displays the consultant’s individual figures. No one else can identify the results of an individual consultant. The ranked comprise single bars, with in addition the 25, 50, and 75 percentiles and are ranked from left to right in the ascending order of the data item being measured. Where percentages are included figures have been rounded up to one decimal point. Unless otherwise stated all analyses represent the 2004 dataset.

A personal ranking sheet for each consultant registering three or more tumours was issued individually to go with this chartbook.

Sarah Fowler
BAUS Cancer Registry (BCR) Manager
October 2005
A. Who took Part and Overall Figures

We note a decrease in returns again from 2003. This is partly due to the cessation of the Scottish Urological Cancer Audit (SUCA) during 2003 and the subsequent need for consultants from Scotland to revert back to returning their data individually. The returns from Scotland have dropped by 75% from a high of 3016 registrations in 2002 to 1192 in 2003 and 748 in 2004. In addition each year sees some centres dropping out and new ones coming in. Ninety two consultants, who appear to still be working took part in 2003 returning 1945 sets of data but did not do so in 2004. Correspondingly 75 consultants took part in 2004 that had not done so in 2003 and provided 2062 sets of data. In addition 19 centres with data included in these analyses have no patients diagnosed after 31st July 2004.

A variety of reasons are cited for failure to return data, the major one being lack of resources.

The growing number of centres using their own in-house systems to return data is to be encouraged if it means that less data is duplicated and returns to BCR are easier for participants. However it is noted that the data returned by many of these systems is not as complete as when returned using the specially designed Microsoft Access database making validation and analyses more complicated. It is to be hoped that these are teething problems that will be resolved shortly.

As in previous years we have incorporated comparison with National Cancer Statistics from 2002/2003 – the latest years available. Comparison with the national data does suggest that our data are representative of the UK as a whole. However when comparing our data with that of the national data we should bear in mind the following:

- Our data are only being collected by urologists. We have no way of estimating the number of urological cancers that are not being seen or diagnosed by urologists. In the case of kidney cancer, it seems that a substantial number are never seen by a urological surgeon.
- These data are being presented within nine months of the completion of the year of data collection and being compared to projected national figures from 2002/2003, which are the latest to be published.
- For the majority of participants, there is no specific funding for data collection and the analysis and presentation is entirely funded by the Section of Oncology.

Chart 1

**BAUS - Register of Newly Presenting Urological Tumours**

**January 1st - December 31st 2004**

**Who took part**

- 423 Consultants from 140 Centres provided data on 24,532 newly presenting urological tumours.
- 51% (214/423) Consultants are members of the Section of Oncology. These Consultants returned 75% of the data.
- 3.5% (871/24532) were from the private patients of 133 Consultants.
- Range of Consultants per Centre = 1 - 13, (Median 3).
- Median number of tumours per Consultant = 47, Range 1 - 312.
- Median number of tumours per Centre = 131, Range 1 - 775.
- 84% (20683/24532) of the data were returned electronically.
Chart 2

**Total Number of Newly Presenting Tumours Reported per Consultant**

Median: 47 (Interquartile Range 17 - 82)

N.B. Excludes data returned by centres as a whole

Chart 3

**Total Number of Newly Presenting Tumours Reported per Centre**

Median: 131 (Interquartile Range 65 - 237)

N.B. Excludes private patients

Total Registrations
Consultant Ranking

Centre Ranking
Chart 4

Number of Newly presenting Tumours by Organ per Consultant
423 Consultants reported 24,532 Tumours
Median Total per Consultant = 47

<table>
<thead>
<tr>
<th>Organ</th>
<th>Total Number Reported</th>
<th>Median per Consultant</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate *</td>
<td>14858</td>
<td>23</td>
<td>0 – 216</td>
</tr>
<tr>
<td>Bladder</td>
<td>6073</td>
<td>11</td>
<td>0 – 71</td>
</tr>
<tr>
<td>Kidney</td>
<td>2104</td>
<td>3</td>
<td>0 – 55</td>
</tr>
<tr>
<td>Testis</td>
<td>750</td>
<td>1</td>
<td>0 – 13</td>
</tr>
<tr>
<td>Pelvis/Ureter</td>
<td>291</td>
<td>0</td>
<td>0 – 11</td>
</tr>
<tr>
<td>Penis</td>
<td>196</td>
<td>0</td>
<td>0 – 8</td>
</tr>
<tr>
<td>Urethra</td>
<td>29</td>
<td>0</td>
<td>0 – 2</td>
</tr>
<tr>
<td>Prostatic Urethra</td>
<td>15</td>
<td>0</td>
<td>0 – 1</td>
</tr>
</tbody>
</table>

* Includes 84 registrations with High Grade PIN only

Chart 5

Total Number of Newly Presenting Tumours Reported per Consultant by Organ where n >=47 (i.e. the median reported per consultant)

N.B. Excludes data returned by centres as a whole
Chart 6

**Total Number of Newly Presenting Tumours Reported per Consultant by Organ where n >=47 (i.e. the median reported per consultant)**

*Ranked by Prostate proportion*

Chart 7

**Overall Data by Organ**

<table>
<thead>
<tr>
<th>Organ</th>
<th>Number Recorded</th>
<th>Percentage of Total (24532)</th>
<th>Mean Age at Diagnosis</th>
<th>Age Range</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate *</td>
<td>14858</td>
<td>60.6</td>
<td>71.4</td>
<td>21-103</td>
<td>14858</td>
<td>-</td>
</tr>
<tr>
<td>Bladder</td>
<td>6073</td>
<td>24.8</td>
<td>72.0</td>
<td>12-101</td>
<td>4488</td>
<td>1497</td>
</tr>
<tr>
<td>Kidney</td>
<td>2104</td>
<td>8.6</td>
<td>65.2</td>
<td>20-102</td>
<td>1336</td>
<td>749</td>
</tr>
<tr>
<td>Testis</td>
<td>750</td>
<td>3.1</td>
<td>38.4</td>
<td>14-101</td>
<td>750</td>
<td>-</td>
</tr>
<tr>
<td>Pelvis/Ureter</td>
<td>291</td>
<td>1.2</td>
<td>70.4</td>
<td>19-94</td>
<td>168</td>
<td>122</td>
</tr>
<tr>
<td>Penis</td>
<td>196</td>
<td>0.8</td>
<td>66.1</td>
<td>28-93</td>
<td>196</td>
<td>-</td>
</tr>
<tr>
<td>Urethra</td>
<td>29</td>
<td>0.1</td>
<td>72.0</td>
<td>36-94</td>
<td>18</td>
<td>11</td>
</tr>
<tr>
<td>Prostatic Urethra</td>
<td>15</td>
<td>0.1</td>
<td>72.9</td>
<td>62-84</td>
<td>15</td>
<td>-</td>
</tr>
<tr>
<td>Other</td>
<td>29</td>
<td>0.1</td>
<td>65.5</td>
<td>19-91</td>
<td>23</td>
<td>6</td>
</tr>
<tr>
<td>Not recorded</td>
<td>187</td>
<td>0.8</td>
<td>67.8</td>
<td>26-90</td>
<td>155</td>
<td>27</td>
</tr>
</tbody>
</table>

* Includes 84 registrations with High Grade PIN only
### Chart 8

**Overall Data by Organ by Year**

<table>
<thead>
<tr>
<th>Organ</th>
<th>2004 Number Recorded</th>
<th>% of Total (24,532)</th>
<th>2003 Number Recorded</th>
<th>% of Total (27,225)</th>
<th>2002 Number Recorded</th>
<th>% of Total (28,351)</th>
<th>2001 Number Recorded</th>
<th>% of Total (26,746)</th>
<th>2000 Number Recorded</th>
<th>% of Total (24,343)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>14858##</td>
<td>60.6</td>
<td>16055#</td>
<td>58.9</td>
<td>16580*</td>
<td>58.5</td>
<td>15099**</td>
<td>56.5</td>
<td>12892</td>
<td>53.0</td>
</tr>
<tr>
<td>Bladder</td>
<td>6073</td>
<td>24.8</td>
<td>7218</td>
<td>26.5</td>
<td>7611</td>
<td>26.8%</td>
<td>7730</td>
<td>28.9</td>
<td>7549</td>
<td>31.0</td>
</tr>
<tr>
<td>Kidney</td>
<td>2104</td>
<td>8.6</td>
<td>2254</td>
<td>8.3</td>
<td>2270</td>
<td>7.3</td>
<td>2071</td>
<td>7.7</td>
<td>2037</td>
<td>8.4</td>
</tr>
<tr>
<td>Testis</td>
<td>750</td>
<td>3.1</td>
<td>910</td>
<td>3.3</td>
<td>984</td>
<td>3.5</td>
<td>963</td>
<td>3.6</td>
<td>980</td>
<td>4.0</td>
</tr>
<tr>
<td>Pelvis/Ureter</td>
<td>291</td>
<td>1.2</td>
<td>342</td>
<td>1.3</td>
<td>382</td>
<td>1.3</td>
<td>358</td>
<td>1.3</td>
<td>371</td>
<td>1.5</td>
</tr>
<tr>
<td>Penis</td>
<td>196</td>
<td>0.8</td>
<td>179</td>
<td>0.6</td>
<td>235</td>
<td>0.8</td>
<td>217</td>
<td>0.8</td>
<td>221</td>
<td>0.9</td>
</tr>
<tr>
<td>Urethra</td>
<td>29</td>
<td>0.1</td>
<td>40</td>
<td>0.15</td>
<td>25</td>
<td>0.09</td>
<td>37</td>
<td>0.14</td>
<td>33</td>
<td>0.14</td>
</tr>
<tr>
<td>Prostatic Urethra</td>
<td>15</td>
<td>0.1</td>
<td>15</td>
<td>0.05</td>
<td>19</td>
<td>0.07</td>
<td>19</td>
<td>0.07</td>
<td>34</td>
<td>0.14</td>
</tr>
<tr>
<td>Other</td>
<td>29</td>
<td>0.1</td>
<td>61</td>
<td>0.2</td>
<td>67</td>
<td>0.25</td>
<td>62</td>
<td>0.23</td>
<td>90</td>
<td>0.37</td>
</tr>
<tr>
<td>Not recorded</td>
<td>187</td>
<td>0.8</td>
<td>151</td>
<td>0.56</td>
<td>178</td>
<td>0.63</td>
<td>190</td>
<td>0.7</td>
<td>136</td>
<td>0.6</td>
</tr>
</tbody>
</table>

Including registrations with High Grade PIN only:
## 84; #176; * 101; ** 109

### Chart 9

**“Other” Organ Tumours**

The 29 “Others” included:

9 Spermatic cord / Scrotum / Paratesticular
4 Adrenal tumours
3 Lymph Nodes
2 Pelvic
1 Colon
1 Urachal
## Total Registrations per Region - 1

Prostate, Bladder, Kidney, Testis, Pelvis/Ureter & Penile Tumours*

<table>
<thead>
<tr>
<th>Region</th>
<th>2004 Total Registrations* BAUS</th>
<th>National figures**</th>
<th>2004 BAUS % National</th>
<th>2003 BAUS % National</th>
<th>% Change from 2003#</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td>21292</td>
<td>41954</td>
<td>50.8%</td>
<td>56.7%</td>
<td>-5.9%</td>
</tr>
<tr>
<td>Scotland</td>
<td>748</td>
<td>3969</td>
<td>18.8%</td>
<td>34.9%</td>
<td>-16.1%</td>
</tr>
<tr>
<td>Wales</td>
<td>1835</td>
<td>3441</td>
<td>53.3%</td>
<td>47.5%</td>
<td>+5.8%</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>438</td>
<td>1165</td>
<td>37.6%</td>
<td>48.6%</td>
<td>-11.0%</td>
</tr>
<tr>
<td>Total UK</td>
<td>24313</td>
<td>50529</td>
<td>48.1%</td>
<td>54.4%</td>
<td>-6.3%</td>
</tr>
</tbody>
</table>

Wales: Welsh Cancer Intelligence & Surveillance Unit - 2003
Scotland: Scottish Cancer Registry, Scottish Cancer Intelligence Group, ISD Scotland - 2002
Northern Ireland: Northern Ireland Cancer Registry - 2003 - www.qub.ac.uk/nicr
# Change in BAUS returns for 2004 cf 2003 as a % of the National figures
<table>
<thead>
<tr>
<th>Cancer Network</th>
<th>Returns 2004</th>
<th>Approximate Population</th>
<th>Returns as % of Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lancashire &amp; South Cumbria</td>
<td>260</td>
<td>1,480,630</td>
<td>0.02</td>
</tr>
<tr>
<td>Greater Manchester &amp; Cheshire</td>
<td>809</td>
<td>2,955,668</td>
<td>0.03</td>
</tr>
<tr>
<td>Merseyside &amp; Cheshire</td>
<td>1255</td>
<td>2,012,568</td>
<td>0.06</td>
</tr>
<tr>
<td>Northern</td>
<td>1391</td>
<td>1,922,929</td>
<td>0.07</td>
</tr>
<tr>
<td>Teeside, South Durham &amp; North Yorkshire</td>
<td>190</td>
<td>1,020,947</td>
<td>0.02</td>
</tr>
<tr>
<td>Yorkshire</td>
<td>1268</td>
<td>2,557,742</td>
<td>0.05</td>
</tr>
<tr>
<td>Humber &amp; Yorkshire Coast</td>
<td>706</td>
<td>1,025,645</td>
<td>0.07</td>
</tr>
<tr>
<td>North Trent</td>
<td>440</td>
<td>1,742,009</td>
<td>0.03</td>
</tr>
<tr>
<td>North West Midlands</td>
<td>252</td>
<td>1,224,333</td>
<td>0.02</td>
</tr>
<tr>
<td>Black Country</td>
<td>309</td>
<td>896,500</td>
<td>0.03</td>
</tr>
<tr>
<td>Pan Birmingham</td>
<td>636</td>
<td>1,612,196</td>
<td>0.04</td>
</tr>
<tr>
<td>Arden</td>
<td>857</td>
<td>969,069</td>
<td>0.09</td>
</tr>
<tr>
<td>Mid Trent</td>
<td>631</td>
<td>1,556,063</td>
<td>0.04</td>
</tr>
<tr>
<td>Derby / Burton</td>
<td>484</td>
<td>667,764</td>
<td>0.07</td>
</tr>
<tr>
<td>Leicestershire, Northamptonshire &amp; Rutland</td>
<td>519</td>
<td>1,502,967</td>
<td>0.03</td>
</tr>
<tr>
<td>Norfolk &amp; Waveney</td>
<td>107</td>
<td>755,785</td>
<td>0.01</td>
</tr>
<tr>
<td>West Anglia</td>
<td>509</td>
<td>1,511,927</td>
<td>0.03</td>
</tr>
<tr>
<td>Mid Anglia</td>
<td>524</td>
<td>978,676</td>
<td>0.05</td>
</tr>
<tr>
<td>South Essex</td>
<td>370</td>
<td>702,606</td>
<td>0.05</td>
</tr>
<tr>
<td>Mount Vernon</td>
<td>724</td>
<td>1,452,009</td>
<td>0.05</td>
</tr>
<tr>
<td>West London</td>
<td>125</td>
<td>1,732,020</td>
<td>0.01</td>
</tr>
<tr>
<td>North London</td>
<td>379</td>
<td>1,178,447</td>
<td>0.03</td>
</tr>
<tr>
<td>North East London</td>
<td>446</td>
<td>1,495,174</td>
<td>0.03</td>
</tr>
<tr>
<td>South East London</td>
<td>439</td>
<td>1,488,199</td>
<td>0.03</td>
</tr>
<tr>
<td>South West London</td>
<td>236</td>
<td>1,539,603</td>
<td>0.02</td>
</tr>
<tr>
<td>Peninsula</td>
<td>605</td>
<td>1,576,186</td>
<td>0.04</td>
</tr>
<tr>
<td>Dorset</td>
<td>1119</td>
<td>692,712</td>
<td>0.16</td>
</tr>
<tr>
<td>Avon, Somerset &amp; Wiltshire</td>
<td>1091</td>
<td>1,983,850</td>
<td>0.05</td>
</tr>
<tr>
<td>3 Counties</td>
<td>679</td>
<td>1,017,912</td>
<td>0.07</td>
</tr>
<tr>
<td>Thames Valley</td>
<td>1413</td>
<td>2,133,676</td>
<td>0.07</td>
</tr>
<tr>
<td>Central South Coast</td>
<td>1565</td>
<td>1,908,300</td>
<td>0.08</td>
</tr>
<tr>
<td>Surrey, West Sussex &amp; Hampshire</td>
<td>0</td>
<td>1,182,807</td>
<td>0</td>
</tr>
<tr>
<td>Sussex</td>
<td>615</td>
<td>1,082,706</td>
<td>0.06</td>
</tr>
<tr>
<td>Kent &amp; Medway</td>
<td>538</td>
<td>1,579,206</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Populations have been calculated from the populations of the constituent PCTs. The population of each PCT was calculated by the summation of the population of their constituent census wards. Each census ward was allocated to a PCT using the postcodes within the ward since ONS have allocated every postcode in England to a PCT.

Source: National Cancer Services Analysis Team – October 2005
### Chart 12

**Total Registrations per Region - 2**

<table>
<thead>
<tr>
<th>Region</th>
<th>Prostate BAUS</th>
<th>National figures*</th>
<th>BAUS % National</th>
<th>Bladder BAUS</th>
<th>National figures*</th>
<th>BAUS % National</th>
<th>Kidney BAUS</th>
<th>National figures*</th>
<th>BAUS % National</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td>13076</td>
<td>26811</td>
<td>48.8</td>
<td>5355</td>
<td>8022</td>
<td>66.8</td>
<td>1746</td>
<td>4660</td>
<td>37.5</td>
</tr>
<tr>
<td>Scotland</td>
<td>384</td>
<td>2335</td>
<td>16.4</td>
<td>229</td>
<td>779</td>
<td>29.4</td>
<td>99</td>
<td>552</td>
<td>17.9</td>
</tr>
<tr>
<td>Wales</td>
<td>1159</td>
<td>2020</td>
<td>57.4</td>
<td>391</td>
<td>891</td>
<td>43.9</td>
<td>197</td>
<td>366</td>
<td>53.8</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>238</td>
<td>715</td>
<td>33.3</td>
<td>97</td>
<td>221</td>
<td>43.9</td>
<td>61</td>
<td>159</td>
<td>38.4</td>
</tr>
<tr>
<td>Total UK</td>
<td>14857</td>
<td>31881</td>
<td>46.6</td>
<td>6072</td>
<td>9913</td>
<td>61.3</td>
<td>2103</td>
<td>5728</td>
<td>36.7</td>
</tr>
</tbody>
</table>

Scotland:Scottish Cancer Registry,Scottish Cancer Intelligence Group, ISD Scotland - 2002
Northern Ireland:Northern Ireland Cancer Registry - 2003 - www.qub.ac.uk/nicr

### Chart 13

**Total Registrations per Region - 3**

<table>
<thead>
<tr>
<th>Region</th>
<th>Testis BAUS</th>
<th>National figures*</th>
<th>BAUS % National</th>
<th>Pelvis/ Ureter BAUS</th>
<th>National figures*</th>
<th>BAUS % National</th>
<th>Penis BAUS</th>
<th>National figures*</th>
<th>BAUS % National</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td>658</td>
<td>1528</td>
<td>43.1</td>
<td>251</td>
<td>596</td>
<td>42.1</td>
<td>165</td>
<td>337</td>
<td>49.0</td>
</tr>
<tr>
<td>Scotland</td>
<td>17</td>
<td>218</td>
<td>7.8</td>
<td>10</td>
<td>55</td>
<td>18.2</td>
<td>8</td>
<td>30</td>
<td>26.7</td>
</tr>
<tr>
<td>Wales</td>
<td>50</td>
<td>113</td>
<td>44.2</td>
<td>23</td>
<td>31</td>
<td>74.2</td>
<td>13</td>
<td>20</td>
<td>65.0</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>25</td>
<td>56</td>
<td>44.6</td>
<td>7</td>
<td>16</td>
<td>43.8</td>
<td>10</td>
<td>9</td>
<td>111.1</td>
</tr>
<tr>
<td>Total UK</td>
<td>752</td>
<td>1915</td>
<td>39.3</td>
<td>291</td>
<td>698</td>
<td>41.7</td>
<td>200</td>
<td>396</td>
<td>50.5</td>
</tr>
</tbody>
</table>

Scotland:Scottish Cancer Registry,Scottish Cancer Intelligence Group, ISD Scotland - 2002
Northern Ireland:Northern Ireland Cancer Registry - 2003 - www.qub.ac.uk/nicr
Chart 14

Laterality by Organ

<table>
<thead>
<tr>
<th>Organ</th>
<th>Total Number Recorded</th>
<th>Laterality recorded &amp; % of total</th>
<th>Left Side *</th>
<th>Right Side *</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kidney</td>
<td>2104</td>
<td>1971 93.7%</td>
<td>968 49.1%</td>
<td>1003</td>
</tr>
<tr>
<td>Testis</td>
<td>750</td>
<td>680 91.0%</td>
<td>324 47.6%</td>
<td>356</td>
</tr>
<tr>
<td>Pelvis/Ureter</td>
<td>291</td>
<td>231 79.4%</td>
<td>110 47.6%</td>
<td>121</td>
</tr>
</tbody>
</table>

* Number and percentage of those where laterality was recorded

Chart 15

- Total number of synchronous bilateral tumours = 14
  13 Kidney
  1 Pelvis / Ureter

- Total number of Tumours registered twice = 97
  (Tertiary referral from another centre or another consultant in the same centre). Only included once in all analyses

- Total number of patients where there were tumours in different organs in the same year = 221
  (including 2 patients with 3 separate tumours)
Chart 16

**Percentage Age Distribution - Prostate Tumours**

BAUS 2004 median: 72 Years; Range 21 - 103 (n= 14,665*)

<table>
<thead>
<tr>
<th>Age Group</th>
<th>BAUS Data</th>
<th>National Figures</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;40</td>
<td>1.1%</td>
<td>0.5%</td>
</tr>
<tr>
<td>40-49</td>
<td>0.5%</td>
<td>0.6%</td>
</tr>
<tr>
<td>50-59</td>
<td>9.4%</td>
<td>8.5%</td>
</tr>
<tr>
<td>60-64</td>
<td>12.8%</td>
<td>7.1%</td>
</tr>
<tr>
<td>65-69</td>
<td>18.8%</td>
<td>17.8%</td>
</tr>
<tr>
<td>70-74</td>
<td>20.7%</td>
<td>19.7%</td>
</tr>
<tr>
<td>75-79</td>
<td>19.7%</td>
<td>19.7%</td>
</tr>
<tr>
<td>80-84</td>
<td>12.9%</td>
<td>13.5%</td>
</tr>
<tr>
<td>&gt;85</td>
<td>9.4%</td>
<td>6.2%</td>
</tr>
</tbody>
</table>

* Age could be calculated when both date of birth and diagnosis date were recorded = 14,665/14,858 = 98.7%

** National figures are for 2002 (England and Scotland), 2003 (Northern Ireland & Wales)

Chart 17

**Percentage Age Distribution - Bladder Tumours - Males**

BAUS 2004 median Males: 73 Years; Range 20 - 101 (n= 4,470*)

<table>
<thead>
<tr>
<th>Age Group</th>
<th>BAUS Males</th>
<th>National Males</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;40</td>
<td>1.1%</td>
<td>0.5%</td>
</tr>
<tr>
<td>40-49</td>
<td>3.2%</td>
<td>2.1%</td>
</tr>
<tr>
<td>50-59</td>
<td>9.6%</td>
<td>9.9%</td>
</tr>
<tr>
<td>60-64</td>
<td>24.1%</td>
<td>23.3%</td>
</tr>
<tr>
<td>65-69</td>
<td>33.9%</td>
<td>35.8%</td>
</tr>
<tr>
<td>70-79</td>
<td>25.2%</td>
<td>36.3%</td>
</tr>
<tr>
<td>&gt;80</td>
<td>26.3%</td>
<td>25.2%</td>
</tr>
</tbody>
</table>

* Sex was recorded in 5985/6073 (99%) bladder tumours (4488 males & 1497 females)
Age could be calculated when both date of birth and diagnosis date were recorded = 4470/4480 (99%) & 1492/1497 (99%)

** National figures are for 2002 (England and Scotland), 2003 (Northern Ireland & Wales)
Chart 18

Percentage Age Distribution - Bladder Tumours - Females
BAUS 2004 median Females: 75 Years; Range 12 - 98 (n= 1,492*)

Percentage in each age group

* Sex was recorded in 5985/6073 (99%) bladder tumours (4488 males & 1497 females)
Age could be calculated when both date of birth and diagnosis date were recorded = 4470/4480 (99%) & 1492/1497 (99%)
** National figures are for 2002 (England and Scotland), 2003 (Northern Ireland & Wales)

Chart 19

Percentage Age Distribution - Kidney Tumours- Males
BAUS 2004 median Males: 66 Years; Range 21 - 102 (n= 1,323*)

Percentage in each age group

* Sex was recorded in 2085/2104 (99.1%) kidney tumours (1336 males & 749 females)
Age could be calculated when both date of birth and diagnosis date were recorded = 1323/1336 (99%) & 742/749 (99%)
** National figures are for 2002 (England and Scotland), 2003 (Northern Ireland & Wales)
Chart 20

Percentage Age Distribution - Kidney Tumours - Females
BAUS 2004 median Females: 67 Years; Range 20-98 (n= 742*)

* Sex was recorded in 2085/2104 (99.1%) kidney tumours (1336 males & 749 females)

Age could be calculated when both date of birth and diagnosis date were recorded = 1323/1336 (99%) & 742/749 (99%)

** National figures are for 2002 (England and Scotland), 2003 (Northern Ireland & Wales)

Chart 21

Percentage Age Distribution - Testicular Tumours
BAUS 2004 median: 36 Years; Range 14-101 (n= 746*)

* Age could be calculated when both date of birth and diagnosis date were recorded = 746/750 (99.5%).

** National figures are for 2002 (England and Scotland), 2003 (Northern Ireland & Wales)
**Chart 22**

**Percentage Age Distribution - Testicular Tumours**

- Seminoma median age: 38 years; Range 19 - 82; (n = 370*)
- Teratoma median age: 30 years; Range 14 - 101; (n = 173*)
- Combined seminoma/teratoma median age: 33 years; Range 18 - 60; (n = 81*)

*Age could be calculated when both date of birth and diagnosis date were recorded = 746/750 (99.5%). Histology was reported in 699 of these tumours. (695/746 = 93.2%), 71 of these were histologies other than the above groups.*

**Chart 23**

**Percentage Age Distribution - Pelvis/Ureteric Tumours - Males**

- BAUS 2004 median Males: 70 Years; Range 19 - 91 (n= 168*)

*Sex was recorded in 290/291 (99.7%) pelvis/ureteric tumours (168 males & 122 females)
Age could be calculated when both date of birth and diagnosis date were recorded = 168/168 (100%) & 122/122 (100%)

**National figures are for 2002 (England and Scotland), 2003 (Northern Ireland & Wales)**
Chart 24

Percentage Age Distribution - Pelvis/Ureteric Tumours - Females

BAUS 2004 median Females: 73 Years; Range 19 -94 (n=122*)

<table>
<thead>
<tr>
<th>Age Group</th>
<th>BAUS Females</th>
<th>National Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;40</td>
<td>0.8</td>
<td>0.3</td>
</tr>
<tr>
<td>40-49</td>
<td>2.1</td>
<td>1.2</td>
</tr>
<tr>
<td>50-59</td>
<td>8.2</td>
<td>8.7</td>
</tr>
<tr>
<td>60-69</td>
<td>23.8</td>
<td>22.2</td>
</tr>
<tr>
<td>70-79</td>
<td>38.5</td>
<td>40.1</td>
</tr>
<tr>
<td>&gt;=80</td>
<td>25.4</td>
<td>25</td>
</tr>
</tbody>
</table>

* Sex was recorded in 290/291 (99.7%) pelvis/ureteric tumours (168 males & 122 females)
** Age could be calculated when both date of birth and diagnosis date were recorded = 168/168 (100%) & 122/122 (100%)

Chart 25

Percentage Age Distribution - Penile Tumours

BAUS 2004 median: 66 Years; Range 28 -93 (n= 182*)

<table>
<thead>
<tr>
<th>Age Group</th>
<th>BAUS data</th>
<th>National Figures</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;40</td>
<td>2.1</td>
<td>3.3</td>
</tr>
<tr>
<td>40-49</td>
<td>10.4</td>
<td>13.3</td>
</tr>
<tr>
<td>50-59</td>
<td>9.6</td>
<td>11.1</td>
</tr>
<tr>
<td>60-69</td>
<td>19.2</td>
<td>17.2</td>
</tr>
<tr>
<td>70-79</td>
<td>26.5</td>
<td>26.5</td>
</tr>
<tr>
<td>&gt;=80</td>
<td>17</td>
<td>18.9</td>
</tr>
</tbody>
</table>

* Age could be calculated when both date of birth and diagnosis date were recorded = 182/196 = 92.8%
** National figures are for 2002 (England and Scotland), 2003 (Northern Ireland & Wales)
B. Referral Source, Priority & Time between Referral, First Consultation, Diagnosis and Definitive Treatment

In this section we have included charts from the 2003 dataset to allow for comparisons.

‘Priority of referral’ has been recorded in 90% of GP referrals and has enabled analysis of patients referred under the two-week rule as distinct from other types of referral*. Eighty-eight percent (88.5%) of GP referrals, under the two-week rule, were seen within 14 days. This is a significant increase at 95% CI from 2002 data when 73% of this group were seen within 14 days.

The overall time from referral to diagnosis has risen from 2002 and 2003 and remains longer than in 1999. The time from consultation to diagnosis was notably shorter in Scotland and Northern Ireland, where the two week targets do not operate, than other parts of the UK but correspondingly the time from referral to consultation was notably longer.

Recording of date of definitive treatment remains a problem with only 69% returns including this item (an small increase from 65% in 2003) and interpretation must still be cautious. In some cases, the date of definitive treatment was recorded as being before the date of diagnosis! Any negative times between diagnosis and definitive treatment date were treated as 0 i.e. definitive treatment date = date of diagnosis.

The delays from referral to definitive treatment are substantial and disease progression during this time should be considered.

Under the new government cancer waiting times targets* (implemented from April 1st 2003 for urological cancers), urgent GP referrals should be seen within 14 days, and first definitive treatment should be within 31 days for testicular cancers and 62 days for all other cancers. None urgent GP referrals should aim to have a maximum of 31 days between diagnosis and first definitive treatment.

* England only – all charts looking at times to consultation, diagnosis and treatment for patients referred under the 2 week rule exclude returns from Scotland, Wales & Northern Ireland.
### Chart 26

**Source of Referral by Organ - 2004**

<table>
<thead>
<tr>
<th>Organ</th>
<th>GP N</th>
<th>GP %</th>
<th>Urologist N</th>
<th>Urologist %</th>
<th>Other N</th>
<th>Other %</th>
<th>Not Recorded N</th>
<th>Not Recorded %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>10760</td>
<td>72.4</td>
<td>841</td>
<td>5.7</td>
<td>2276</td>
<td>15.3</td>
<td>981</td>
<td>6.6</td>
</tr>
<tr>
<td>Bladder</td>
<td>4475</td>
<td>73.7</td>
<td>185</td>
<td>3.0</td>
<td>1054</td>
<td>17.4</td>
<td>359</td>
<td>5.9</td>
</tr>
<tr>
<td>Kidney</td>
<td>887</td>
<td>42.2</td>
<td>214</td>
<td>10.2</td>
<td>861</td>
<td>40.9</td>
<td>142</td>
<td>6.7</td>
</tr>
<tr>
<td>Testis</td>
<td>566</td>
<td>75.5</td>
<td>21</td>
<td>2.8</td>
<td>123</td>
<td>16.4</td>
<td>40</td>
<td>5.3</td>
</tr>
<tr>
<td>Pelvis/Ureter</td>
<td>173</td>
<td>59.5</td>
<td>29</td>
<td>10.0</td>
<td>68</td>
<td>23.4</td>
<td>21</td>
<td>7.2</td>
</tr>
<tr>
<td>Penis</td>
<td>105</td>
<td>53.6</td>
<td>36</td>
<td>18.4</td>
<td>44</td>
<td>22.4</td>
<td>11</td>
<td>5.6</td>
</tr>
<tr>
<td>Urethra</td>
<td>12</td>
<td>41.4</td>
<td>2</td>
<td>6.9</td>
<td>12</td>
<td>41.4</td>
<td>3</td>
<td>10.3</td>
</tr>
<tr>
<td>Prostatic Urethra</td>
<td>9</td>
<td>60.0</td>
<td>1</td>
<td>6.7</td>
<td>4</td>
<td>26.7</td>
<td>1</td>
<td>6.7</td>
</tr>
<tr>
<td>Other or Not Recorded</td>
<td>136</td>
<td>63.0</td>
<td>11</td>
<td>5.1</td>
<td>35</td>
<td>16.2</td>
<td>34</td>
<td>15.7</td>
</tr>
<tr>
<td>Totals</td>
<td>17123</td>
<td>69.8</td>
<td>1340</td>
<td>5.5</td>
<td>4477</td>
<td>18.2</td>
<td>1592</td>
<td>6.5</td>
</tr>
</tbody>
</table>

### Chart 27

**Source of Referral by Organ - 2003**

<table>
<thead>
<tr>
<th>Organ</th>
<th>GP N</th>
<th>GP %</th>
<th>Urologist N</th>
<th>Urologist %</th>
<th>Other N</th>
<th>Other %</th>
<th>Not Recorded N</th>
<th>Not Recorded %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>11235</td>
<td>70.0</td>
<td>1631</td>
<td>10.2</td>
<td>2161</td>
<td>13.5</td>
<td>1028</td>
<td>6.4</td>
</tr>
<tr>
<td>Bladder</td>
<td>5335</td>
<td>73.9</td>
<td>353</td>
<td>4.9</td>
<td>1113</td>
<td>15.4</td>
<td>417</td>
<td>5.8</td>
</tr>
<tr>
<td>Kidney</td>
<td>980</td>
<td>43.5</td>
<td>270</td>
<td>12.0</td>
<td>877</td>
<td>38.9</td>
<td>127</td>
<td>5.6</td>
</tr>
<tr>
<td>Testis</td>
<td>622</td>
<td>68.4</td>
<td>96</td>
<td>10.5</td>
<td>143</td>
<td>15.7</td>
<td>49</td>
<td>5.4</td>
</tr>
<tr>
<td>Pelvis/Ureter</td>
<td>194</td>
<td>56.7</td>
<td>33</td>
<td>9.6</td>
<td>85</td>
<td>24.9</td>
<td>30</td>
<td>8.8</td>
</tr>
<tr>
<td>Penis</td>
<td>104</td>
<td>58.1</td>
<td>22</td>
<td>12.3</td>
<td>37</td>
<td>20.7</td>
<td>16</td>
<td>8.9</td>
</tr>
<tr>
<td>Urethra</td>
<td>18</td>
<td>45.0</td>
<td>4</td>
<td>10.0</td>
<td>16</td>
<td>40.0</td>
<td>2</td>
<td>5.0</td>
</tr>
<tr>
<td>Prostatic Urethra</td>
<td>11</td>
<td>73.3</td>
<td>1</td>
<td>6.7</td>
<td>3</td>
<td>20.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Other or Not Recorded</td>
<td>111</td>
<td>52.4</td>
<td>42</td>
<td>19.8</td>
<td>33</td>
<td>15.6</td>
<td>26</td>
<td>12.3</td>
</tr>
<tr>
<td>Totals</td>
<td>18610</td>
<td>68.4</td>
<td>2452</td>
<td>9.0</td>
<td>4468</td>
<td>16.4</td>
<td>1695</td>
<td>6.2</td>
</tr>
</tbody>
</table>
“Other” Sources of Referral by Organ included:

<table>
<thead>
<tr>
<th>Source</th>
<th>Prostate</th>
<th>Bladder</th>
<th>Kidney</th>
<th>Testis</th>
<th>Pelvis/Ureter</th>
<th>Penis</th>
<th>Urethra</th>
<th>Prostatic Urethra</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consultant Physicians</td>
<td>371</td>
<td>172</td>
<td>268</td>
<td>13</td>
<td>2</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consultant Surgeons</td>
<td>328</td>
<td>147</td>
<td>218</td>
<td>23</td>
<td>7</td>
<td>3</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>A &amp; E</td>
<td>266</td>
<td>253</td>
<td>80</td>
<td>30</td>
<td>4</td>
<td>5</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Gynaecology</td>
<td>1</td>
<td>71</td>
<td>17</td>
<td>1</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Care of Elderly</td>
<td>54</td>
<td>23</td>
<td>19</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematology</td>
<td>17</td>
<td>6</td>
<td>14</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncologists</td>
<td>25</td>
<td>9</td>
<td>37</td>
<td>7</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discovered during Urological Follow-up</td>
<td>503</td>
<td>118</td>
<td>35</td>
<td>2</td>
<td>8</td>
<td>5</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Radiology</td>
<td>1</td>
<td>2</td>
<td>10</td>
<td>14</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incidental Finding</td>
<td>128</td>
<td>36</td>
<td>30</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>259</td>
<td>93</td>
<td>66</td>
<td>16</td>
<td>3</td>
<td>7</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

Source of Referral by Region - 2004
Region could be identified in 24529/24532 tumours (99.9%)

<table>
<thead>
<tr>
<th>Region</th>
<th>GP N</th>
<th>Urologist %</th>
<th>Other N</th>
<th>Other %</th>
<th>Not Recorded N</th>
<th>Not Recorded %</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td>15152</td>
<td>70.5</td>
<td>1121</td>
<td>5.2</td>
<td>3750</td>
<td>17.4</td>
</tr>
<tr>
<td>Scotland</td>
<td>520</td>
<td>69.4</td>
<td>39</td>
<td>5.2</td>
<td>171</td>
<td>22.8</td>
</tr>
<tr>
<td>Wales</td>
<td>1231</td>
<td>66.9</td>
<td>109</td>
<td>5.9</td>
<td>414</td>
<td>22.5</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>219</td>
<td>49.7</td>
<td>71</td>
<td>16.1</td>
<td>141</td>
<td>32.0</td>
</tr>
<tr>
<td>Total UK</td>
<td>17122</td>
<td>69.8</td>
<td>1340</td>
<td>5.5</td>
<td>4476</td>
<td>18.2</td>
</tr>
</tbody>
</table>
### Chart 30

**Priority of GP Referrals by Organ 2004**

<table>
<thead>
<tr>
<th>Priority</th>
<th>Prostate</th>
<th>Bladder</th>
<th>Kidney</th>
<th>Testis</th>
<th>Pelvis/Ureter</th>
<th>Penis</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Under 2 week rule</td>
<td>3955</td>
<td>36.8%</td>
<td>1772</td>
<td>39.6%</td>
<td>379</td>
<td>42.7%</td>
<td>336</td>
</tr>
<tr>
<td>Emergency</td>
<td>306</td>
<td>2.8%</td>
<td>221</td>
<td>4.9%</td>
<td>66</td>
<td>7.4%</td>
<td>21</td>
</tr>
<tr>
<td>Urgent</td>
<td>2816</td>
<td>26.2%</td>
<td>1210</td>
<td>27.0%</td>
<td>246</td>
<td>27.7%</td>
<td>142</td>
</tr>
<tr>
<td>Routine</td>
<td>2671</td>
<td>24.8%</td>
<td>884</td>
<td>19.8%</td>
<td>115</td>
<td>13.0%</td>
<td>38</td>
</tr>
<tr>
<td>Discovered during urological</td>
<td>29</td>
<td>0.3%</td>
<td>5</td>
<td>0.1%</td>
<td>3</td>
<td>0.3%</td>
<td>1</td>
</tr>
<tr>
<td>follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown / Not Recorded</td>
<td>983</td>
<td>9.1%</td>
<td>383</td>
<td>8.6%</td>
<td>78</td>
<td>8.8%</td>
<td>28</td>
</tr>
<tr>
<td>Total</td>
<td>10760</td>
<td>100%</td>
<td>4475</td>
<td>100%</td>
<td>887</td>
<td>100%</td>
<td>566</td>
</tr>
</tbody>
</table>

### Chart 31

**Priority of GP Referrals by Organ 2003**

<table>
<thead>
<tr>
<th>Priority</th>
<th>Prostate</th>
<th>Bladder</th>
<th>Kidney</th>
<th>Testis</th>
<th>Pelvis/Ureter</th>
<th>Penis</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Under 2 week rule</td>
<td>3537</td>
<td>31.5%</td>
<td>1970</td>
<td>36.9%</td>
<td>375</td>
<td>38.3%</td>
<td>362</td>
</tr>
<tr>
<td></td>
<td>11235</td>
<td>100%</td>
<td>(5335)</td>
<td>100%</td>
<td>(980)</td>
<td>100%</td>
<td>(622)</td>
</tr>
<tr>
<td>Under 2 week rule downgraded</td>
<td>38</td>
<td>0.3%</td>
<td>18</td>
<td>0.3%</td>
<td>1</td>
<td>0.1%</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emergency</td>
<td>399</td>
<td>3.6%</td>
<td>262</td>
<td>4.9%</td>
<td>83</td>
<td>8.3%</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>3213</td>
<td>100%</td>
<td>1575</td>
<td>100%</td>
<td>293</td>
<td>100%</td>
<td>145</td>
</tr>
<tr>
<td>Routine</td>
<td>2887</td>
<td>28.6%</td>
<td>1041</td>
<td>29.5%</td>
<td>135</td>
<td>29.9%</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discovered during urological</td>
<td>28</td>
<td>0.2%</td>
<td>5</td>
<td>0.1%</td>
<td>1</td>
<td>0.1%</td>
<td>1</td>
</tr>
<tr>
<td>follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown / Not Recorded</td>
<td>1133</td>
<td>10.1%</td>
<td>464</td>
<td>8.7%</td>
<td>92</td>
<td>9.4%</td>
<td>42</td>
</tr>
<tr>
<td>Total</td>
<td>10760</td>
<td>100%</td>
<td>4475</td>
<td>100%</td>
<td>887</td>
<td>100%</td>
<td>566</td>
</tr>
</tbody>
</table>
Chart 32

**Median Time to First Consultation and Diagnosis in Days by Referral Source in Days Excluding tumours diagnosed before Referral** - 2004

Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date (N = 20,189/24,532 = 82.3% tumours). Referral Source was recorded in 20,020/20,189 cases: GP - 15809/17123 = 92.3%; Urologist 753/1340 = 56.2%; Other 3458/4477 = 77.2%.

# Referral priority was recorded in 96.4% (14601/15152) GP referrals in England where 2 week rule operates.

Chart 33

**Times to First Consultation and Diagnosis in Days when referred by GP (15,809 tumours) Excluding those diagnosed before Referral - 2004**

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to First Consultation</th>
<th>Time from First Consultation to Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 *</td>
<td>N 903</td>
<td>% 5.7</td>
</tr>
<tr>
<td>1 – 14</td>
<td>N 6999</td>
<td>% 44.3</td>
</tr>
<tr>
<td>15 – 28</td>
<td>N 2864</td>
<td>% 18.1</td>
</tr>
<tr>
<td>29 – 60</td>
<td>N 3096</td>
<td>% 19.6</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>N 1947</td>
<td>% 12.3</td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed at first consultation.
### Chart 34

**Times to First Consultation and Diagnosis in Days**  
when referred by GP under the 2 week rule (5,651 tumours)  
Excluding those diagnosed before Referral - 2004

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to first Consultation</th>
<th>Time from first consultation to Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>0 *</td>
<td>88</td>
<td>1.6</td>
</tr>
<tr>
<td>1 – 14</td>
<td>4913</td>
<td>86.9</td>
</tr>
<tr>
<td>15 – 28</td>
<td>452</td>
<td>8.0</td>
</tr>
<tr>
<td>29 - 60</td>
<td>132</td>
<td>2.3</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>66</td>
<td>1.2</td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed at first consultation

### Chart 35

**Times to First Consultation and Diagnosis in Days**  
when referred by a Urologist (753 tumours)  
Excluding those diagnosed before Referral - 2004

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to first Consultation</th>
<th>Time from first consultation to Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>0 *</td>
<td>216</td>
<td>28.7</td>
</tr>
<tr>
<td>1 – 14</td>
<td>168</td>
<td>22.3</td>
</tr>
<tr>
<td>15 – 28</td>
<td>147</td>
<td>19.5</td>
</tr>
<tr>
<td>29 - 60</td>
<td>136</td>
<td>18.1</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>86</td>
<td>11.4</td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed at first consultation
Chart 36

Times to First Consultation and Diagnosis in Days when referred by “Other” source (3,458 tumours) Excluding those diagnosed before Referral - 2004

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to first Consultation</th>
<th>Time from first consultation to Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>0 *</td>
<td>1264</td>
<td>36.6</td>
</tr>
<tr>
<td>1 – 14</td>
<td>952</td>
<td>27.5</td>
</tr>
<tr>
<td>15 – 28</td>
<td>471</td>
<td>13.6</td>
</tr>
<tr>
<td>29 - 60</td>
<td>469</td>
<td>13.6</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>302</td>
<td>8.7</td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed at first consultation

Chart 37

Median Time to First Consultation and Diagnosis in Days by Region for tumours referred by GP - 2004 Excluding tumours diagnosed before Referral*

* Times were calculated when region, dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date  N = 15,808/17,122 = 92.3% of GP referrals
Chart 38

**Median Time to First Consultation and Diagnosis in Days by Region for tumours referred by GP - 2003**

**Excluding tumours diagnosed before Referral**

*Times were calculated when region, dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date  N = 16,930/18,610 = 90.9% of GP referrals*

![Chart showing times to first consultation and diagnosis](chart.png)

Chart 39

**Times to First Consultation and Diagnosis in Days by Region for tumours referred by GP - 2004**

**Excluding tumours diagnosed before Referral**

<table>
<thead>
<tr>
<th>Region</th>
<th>Time to Consultation</th>
<th></th>
<th>Time to Diagnosis</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Mean</td>
<td>Range (0-95 %) in days</td>
<td>Median</td>
</tr>
<tr>
<td>Total England (13998 tumours)</td>
<td>14</td>
<td>33.1</td>
<td>0 – 90</td>
<td>36</td>
</tr>
<tr>
<td>Scotland (476 tumours)</td>
<td>39</td>
<td>46.8</td>
<td>0 – 99</td>
<td>23</td>
</tr>
<tr>
<td>Wales (1134 tumours)</td>
<td>21</td>
<td>38.8</td>
<td>0 – 129</td>
<td>49</td>
</tr>
<tr>
<td>Northern Ireland (200 tumours)</td>
<td>41</td>
<td>58.3</td>
<td>0 – 151</td>
<td>23</td>
</tr>
</tbody>
</table>
### Chart 40

**Times to First Consultation and Diagnosis in Days by Region for tumours referred by GP - 2003**

*Excluding tumours diagnosed before Referral*

<table>
<thead>
<tr>
<th>Region</th>
<th>Time to Consultation</th>
<th>Time to Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Mean</td>
</tr>
<tr>
<td>Total England (14869 tumours)</td>
<td>15</td>
<td>30.4</td>
</tr>
<tr>
<td>Scotland (801 tumours)</td>
<td>32</td>
<td>44.4</td>
</tr>
<tr>
<td>Wales (952 tumours)</td>
<td>18</td>
<td>36.5</td>
</tr>
<tr>
<td>Northern Ireland (308 tumours)</td>
<td>34</td>
<td>49.3</td>
</tr>
</tbody>
</table>

### Chart 41

**Median Time to First Consultation and Diagnosis in Days by Organ**

*Excluding tumours diagnosed before Referral*

<table>
<thead>
<tr>
<th>Organ</th>
<th>Time From Referral to Consultation</th>
<th>Time from Consultation to Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate (10997)</td>
<td>16</td>
<td>35</td>
</tr>
<tr>
<td>Bladder (5246)</td>
<td>14</td>
<td>31</td>
</tr>
<tr>
<td>Kidney (1481)</td>
<td>10</td>
<td>34</td>
</tr>
<tr>
<td>Testis (662)</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>Pelvis/Ureter (227)</td>
<td>13</td>
<td>66</td>
</tr>
<tr>
<td>Penis (152)</td>
<td>11</td>
<td>14</td>
</tr>
</tbody>
</table>

*Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date (N = 20,189/24,532 = 82.3% tumours - Bladder = 5246/6073 = 86.4%; Kidney = 1481/2104 = 70.4%; Testis = 662/750 = 88.3%; Pelvis/Ureter = 227/291 =78.0%; Penis = 152/196 = 77.6%.
Prostate tumours were only included if they were >T1b = 10997/13017 =84.5%*
Chart 42

Median Time to First Consultation and Diagnosis in Days by Organ
Excluding tumours diagnosed before Referral*

2003 dataset

* Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date (N = 21,294/27,225 = 78.2% tumours - Bladder = 6013/7218 = 83.3%; Kidney = 1506/2254 = 66.8%; Testis = 711/910 = 78.1%; Pelvis/Ureter = 254/342 =74.3%; Penis = 134/179 = 74.9%. Prostate tumours were only included if they were >T1b = 11545/14015 =82.4%.

Chart 43

Median Time to First Consultation and Diagnosis in Days by Organ
When referred by GP under the 2 week rule
Excluding tumours diagnosed before Referral*

2004 dataset

* Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date (N = 20,189/24,532 = 82.3% tumours - Bladder = 1656/1767 = 93.7%; Kidney = 327/378 = 86.5%; Testis = 302/336 = 89.9%; Pelvis/Ureter = 58/64 =90.6%; Penis = 34/42 = 81.0%. Prostate tumours were only included if they > T1b = 3050/3233 = 94.3%.
Chart 44

Median Time to First Consultation and Diagnosis in Days by Organ
When referred by GP under the 2 week rule
Excluding tumours diagnosed before Referral*

2003 dataset

<table>
<thead>
<tr>
<th>Organ</th>
<th>Time From Referral to Consultation</th>
<th>Time from Consultation to Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate (3020)</td>
<td>10</td>
<td>23</td>
</tr>
<tr>
<td>Bladder (1800)</td>
<td>11</td>
<td>32</td>
</tr>
<tr>
<td>Kidney (307)</td>
<td>9</td>
<td>40</td>
</tr>
<tr>
<td>Testis (335)</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>Pelvis/Ureter (61)</td>
<td>10</td>
<td>62</td>
</tr>
<tr>
<td>Penis (33)</td>
<td>9</td>
<td>12</td>
</tr>
</tbody>
</table>

2004:

- Time From Referral to Consultation: 14 days
- Time from Consultation to Diagnosis: Median = 34 days, Mean = 87.2 days, Range (0 – 95%): 0 – 315 days

2003:

- Time From Referral to Consultation: 14 days
- Time from Consultation to Diagnosis: Median = 30 days, Mean = 91.5 days, Range (0 – 95%): 0 – 359 days

2002:

- Time From Referral to Consultation: 17 days
- Time from Consultation to Diagnosis: Median = 29 days, Mean = 85.6 days, Range (0 – 95%): 0 – 332 days

2001:

- Time From Referral to Consultation: 19 days
- Time from Consultation to Diagnosis: Median = 30 days, Mean = 87.2 days, Range (0 – 95%): 0 – 327 days

2000:

- Time From Referral to Consultation: 22 days
- Time from Consultation to Diagnosis: Median = 29 days, Mean = 77.0 days, Range (0 – 95%): 0 – 272 days

1999:

- Time From Referral to Consultation: 53 days
- Time from Consultation to Diagnosis: Median = 53 days, Mean = 84.7 days, Range (0 – 95%): 0 – 282 days

* Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date (N = 21,294/27,225 = 78.2% tumours - Bladder = 1800/1904 = 94.5%; Kidney = 307/359 = 85.5%; Testis = 335/358 = 93.6%; Pelvis/Ureter = 61/67 = 91.0%; Penis = 33/34 = 97.1%.
Prostate tumours were only included if they > T1b = 3020/3189 = 94.7%

Chart 45

Times to First Consultation and Diagnosis in Days - All Referrals
Excluding Patients Diagnosed before Referral

<table>
<thead>
<tr>
<th>Year</th>
<th>Time between Referral and First Consultation in Days</th>
<th>Time between First Consultation and Diagnosis in Days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Mean</td>
</tr>
<tr>
<td>2004</td>
<td>14</td>
<td>36.6</td>
</tr>
<tr>
<td>2003</td>
<td>14</td>
<td>31.3</td>
</tr>
<tr>
<td>2002</td>
<td>17</td>
<td>43.9</td>
</tr>
<tr>
<td>2001</td>
<td>19</td>
<td>34.0</td>
</tr>
<tr>
<td>2000</td>
<td>22</td>
<td>35.1</td>
</tr>
<tr>
<td>1999</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* In 1999 only referral date and diagnosis date were recorded therefore these figures represent total time to diagnosis

28
Chart 46

Median Total Times to Diagnosis in Days - All Referrals
Excluding Patients Diagnosed before Referral

Median number of days between referral and diagnosis

<table>
<thead>
<tr>
<th>Year</th>
<th>Median</th>
<th>Mean</th>
<th>Range (0 – 95%)</th>
<th>Median</th>
<th>Mean</th>
<th>Range (0 – 95%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>59</td>
<td>184.1</td>
<td>0 – 599</td>
<td>31</td>
<td>41.1</td>
<td>0 – 158</td>
</tr>
<tr>
<td>2001</td>
<td>57</td>
<td>90.7</td>
<td>0 – 285</td>
<td>0</td>
<td>7.4</td>
<td>0 – 87</td>
</tr>
<tr>
<td>2002</td>
<td>55</td>
<td>93.8</td>
<td>0 – 272</td>
<td>0</td>
<td>6.9</td>
<td>0 – 97</td>
</tr>
<tr>
<td>2003</td>
<td>55</td>
<td>28.0</td>
<td>0 – 103</td>
<td>0</td>
<td>4.1</td>
<td>0 – 17</td>
</tr>
<tr>
<td>2004</td>
<td>57</td>
<td>144.7</td>
<td>0 – 308</td>
<td>6</td>
<td>15.2</td>
<td>0 – 102</td>
</tr>
</tbody>
</table>

Chart 47

Times to Definitive Treatment in Days by Organ - 2004
Excluding tumours diagnosed or treated before referral

<table>
<thead>
<tr>
<th>Organ</th>
<th>Time between Referral and Definitive Treatment in days</th>
<th>Time between Diagnosis and Definitive Treatment in days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Mean</td>
</tr>
<tr>
<td>Prostate (7233)</td>
<td>112</td>
<td>184.1</td>
</tr>
<tr>
<td>Bladder (2612)</td>
<td>63</td>
<td>90.7</td>
</tr>
<tr>
<td>Kidney (844)</td>
<td>65</td>
<td>93.8</td>
</tr>
<tr>
<td>Testis (346)</td>
<td>16</td>
<td>28.0</td>
</tr>
<tr>
<td>Pelvis/Ureter (145)</td>
<td>117</td>
<td>144.7</td>
</tr>
<tr>
<td>Penis (89)</td>
<td>56</td>
<td>121.6</td>
</tr>
</tbody>
</table>

Definitive treatment date was recorded in 69.0% tumours (16923/24532)
### Chart 48

**Times to Definitive Treatment in Days by Organ - 2003**

*Excluding tumours diagnosed or treated before referral*

<table>
<thead>
<tr>
<th>Organ</th>
<th>Time between Referral and Definitive Treatment in days</th>
<th>Time between Diagnosis and Definitive Treatment in days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Mean</td>
</tr>
<tr>
<td>Prostate (7035)</td>
<td>107</td>
<td>188.1</td>
</tr>
<tr>
<td>Bladder (3151)</td>
<td>65</td>
<td>104.8</td>
</tr>
<tr>
<td>Kidney (862)</td>
<td>63</td>
<td>98.0</td>
</tr>
<tr>
<td>Testis (373)</td>
<td>16</td>
<td>67.6</td>
</tr>
<tr>
<td>Pelvis/Ureter (171)</td>
<td>111</td>
<td>174.7</td>
</tr>
<tr>
<td>Penis (82)</td>
<td>48</td>
<td>80.1</td>
</tr>
</tbody>
</table>

Definitive treatment date was recorded in 65.1% tumours (17730/27225)

### Chart 49

**Times to Definitive Treatment in Days by Organ - 2004**

*When referred by GP under the two week rule excluding tumours diagnosed or treated before referral*

<table>
<thead>
<tr>
<th>Organ</th>
<th>Time between Referral and Definitive Treatment in days</th>
<th>Time between Diagnosis and Definitive Treatment in days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Mean</td>
</tr>
<tr>
<td>Prostate (1995)</td>
<td>75</td>
<td>106.1</td>
</tr>
<tr>
<td>Bladder (779)</td>
<td>52</td>
<td>66.1</td>
</tr>
<tr>
<td>Kidney (174)</td>
<td>75</td>
<td>90.2</td>
</tr>
<tr>
<td>Testis (169)</td>
<td>17</td>
<td>23.9</td>
</tr>
<tr>
<td>Pelvis/Ureter (35)</td>
<td>134</td>
<td>147.7</td>
</tr>
<tr>
<td>Penis (16)</td>
<td>56</td>
<td>134.4</td>
</tr>
</tbody>
</table>

Definitive treatment date was recorded in 72.9% tumours referred by GP under the 2 week rule (4429/6073)
Chart 50

Times to Definitive Treatment in Days by Organ - 2003
When referred by GP under the two week rule excluding tumours diagnosed or treated before referral

<table>
<thead>
<tr>
<th>Organ</th>
<th>Time between Referral and Definitive Treatment in days</th>
<th>Time between Diagnosis and Definitive Treatment in days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Mean</td>
</tr>
<tr>
<td>Prostate (1769)</td>
<td>67</td>
<td>98.3</td>
</tr>
<tr>
<td>Bladder (894)</td>
<td>54</td>
<td>72.8</td>
</tr>
<tr>
<td>Kidney (176)</td>
<td>71</td>
<td>88.9</td>
</tr>
<tr>
<td>Testis (163)</td>
<td>17</td>
<td>99.5</td>
</tr>
<tr>
<td>Pelvis/Ureter (41)</td>
<td>104</td>
<td>133.0</td>
</tr>
<tr>
<td>Penis (21)</td>
<td>40</td>
<td>68.6</td>
</tr>
</tbody>
</table>

Definitive treatment date was recorded in 70.6% tumours referred by GP under the 2 week rule (4281/6066)

Chart 51

Times to Definitive Treatment in Days - Prostate Cancer by Stage - 2004
When referred by GP under the two week rule excluding tumours diagnosed or treated before referral

<table>
<thead>
<tr>
<th>Stage</th>
<th>Time between Referral and Definitive Treatment in days</th>
<th>Time between Diagnosis and Definitive Treatment in days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Median</td>
</tr>
<tr>
<td>Stage I (T1a N0 M0 Well Differentiated)</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Stage II (T1a N0 M0 Mod or Poor differentiation T1b, 1c, 1, 2, N0 M0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1a – 8</td>
<td>117</td>
<td>149.2</td>
</tr>
<tr>
<td>T1b – 8</td>
<td>118</td>
<td>149.8</td>
</tr>
<tr>
<td>Any differentiation</td>
<td>123</td>
<td>162.9</td>
</tr>
<tr>
<td>Stage III (T3 N0 M0 Any differentiation)</td>
<td>465</td>
<td>63</td>
</tr>
<tr>
<td>Stage IV (T4 N0 M0 Any differentiation Any T N1 M0 Any differentiation Any T Any N M1 Any differentiation)</td>
<td>282</td>
<td>43</td>
</tr>
</tbody>
</table>
### Chart 52

**Times to Definitive Treatment in Days - Prostate Cancer by Stage - 2003**  
When referred by GP under the two week rule  
excluding tumours diagnosed or treated before referral

<table>
<thead>
<tr>
<th>Stage</th>
<th>Time between Referral and Definitive Treatment in days</th>
<th>Time between Diagnosis and Definitive Treatment in days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Median</td>
</tr>
<tr>
<td>Stage I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(T1a N0 M0 Well Differentiated)</td>
<td>6</td>
<td>114</td>
</tr>
<tr>
<td>Stage II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(T1a N0 M0 Mod or Poor differentiation T1b, 1c, 1, 2, N0 M0 Any differentiation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TI – 52</td>
<td></td>
<td>113</td>
</tr>
<tr>
<td>T1a – 5</td>
<td></td>
<td>110</td>
</tr>
<tr>
<td>T1b – 4</td>
<td></td>
<td>96</td>
</tr>
<tr>
<td>T1c – 154</td>
<td></td>
<td>119</td>
</tr>
<tr>
<td>T2 – 410</td>
<td></td>
<td>84</td>
</tr>
<tr>
<td>Stage III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(T3 N0 M0 Any differentiation)</td>
<td>464</td>
<td>60</td>
</tr>
<tr>
<td>Stage IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(T4 N0 M0 Any differentiation Any T N1 M0 Any differentiation Any T Any N M1 Any differentiation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>337</td>
<td>42</td>
</tr>
</tbody>
</table>

### Chart 53

**Times to First Consultation, Diagnosis and Definitive Treatment in Days by Prostate (10997 tumours)- 2004 dataset**  
Excluding tumours diagnosed before Referral and those with T1a or T1b

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to first Consultation</th>
<th>Time from first consultation to Diagnosis</th>
<th>Time from Diagnosis to Definitive Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>0 *</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 – 14</td>
<td>1012</td>
<td>9.2</td>
<td>1529</td>
</tr>
<tr>
<td>15 – 28</td>
<td>4230</td>
<td>38.5</td>
<td>1672</td>
</tr>
<tr>
<td>29 - 60</td>
<td>2012</td>
<td>18.3</td>
<td>1582</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>2250</td>
<td>20.5</td>
<td>2802</td>
</tr>
<tr>
<td>Not Recorded</td>
<td>1493</td>
<td>13.6</td>
<td>3412</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed and/or treated at first consultation
### Chart 54

**Times to First Consultation, Diagnosis and Definitive Treatment in Days by Prostate (11545 tumours)- 2003 dataset**

Excluding tumours diagnosed before Referral and those with T1a or T1b

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to first Consultation</th>
<th>Time from first consultation to Diagnosis</th>
<th>Time from Diagnosis to Definitive Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>0 *</td>
<td>1008</td>
<td>8.7</td>
<td>1596</td>
</tr>
<tr>
<td>1 – 14</td>
<td>4289</td>
<td>37.2</td>
<td>2069</td>
</tr>
<tr>
<td>15 – 28</td>
<td>2238</td>
<td>19.4</td>
<td>1846</td>
</tr>
<tr>
<td>29 - 60</td>
<td>2395</td>
<td>20.7</td>
<td>2596</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>1615</td>
<td>14.0</td>
<td>3438</td>
</tr>
<tr>
<td>Not Recorded</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed and/or treated at first consultation

### Chart 55

**Times to First Consultation, Diagnosis and Definitive Treatment in Days by Bladder (5246 tumours)- 2004 dataset**

Excluding tumours diagnosed before Referral

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to first Consultation</th>
<th>Time from first consultation to Diagnosis</th>
<th>Time from Diagnosis to Definitive Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>0 *</td>
<td>706</td>
<td>13.5</td>
<td>583</td>
</tr>
<tr>
<td>1 – 14</td>
<td>2170</td>
<td>41.4</td>
<td>883</td>
</tr>
<tr>
<td>15 – 28</td>
<td>906</td>
<td>17.3</td>
<td>961</td>
</tr>
<tr>
<td>29 - 60</td>
<td>961</td>
<td>18.3</td>
<td>1613</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>503</td>
<td>9.6</td>
<td>1206</td>
</tr>
<tr>
<td>Not Recorded</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed and/or treated at first consultation
Chart 56

Times to First Consultation, Diagnosis and Definitive Treatment in Days by Bladder (6013 tumours)- 2003 dataset
Excluding tumours diagnosed before Referral

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to first Consultation</th>
<th>Time from first consultation to Diagnosis</th>
<th>Time from Diagnosis to Definitive Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>0 *</td>
<td>691</td>
<td>11.5</td>
<td>617</td>
</tr>
<tr>
<td>1 – 14</td>
<td>2337</td>
<td>38.9</td>
<td>1099</td>
</tr>
<tr>
<td>15 – 28</td>
<td>1196</td>
<td>19.9</td>
<td>1127</td>
</tr>
<tr>
<td>29 - 60</td>
<td>1178</td>
<td>19.6</td>
<td>1724</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>611</td>
<td>10.2</td>
<td>1446</td>
</tr>
<tr>
<td>Not Recorded</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed and/or treated at first consultation

Chart 57

Times to First Consultation, Diagnosis and Definitive Treatment in Days by Kidney (1481 tumours)- 2004 dataset
Excluding tumours diagnosed before Referral

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to first Consultation</th>
<th>Time from first consultation to Diagnosis</th>
<th>Time from Diagnosis to Definitive Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>0 *</td>
<td>290</td>
<td>19.6</td>
<td>152</td>
</tr>
<tr>
<td>1 – 14</td>
<td>676</td>
<td>45.6</td>
<td>281</td>
</tr>
<tr>
<td>15 – 28</td>
<td>253</td>
<td>17.1</td>
<td>217</td>
</tr>
<tr>
<td>29 - 60</td>
<td>168</td>
<td>11.3</td>
<td>393</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>94</td>
<td>6.3</td>
<td>438</td>
</tr>
<tr>
<td>Not Recorded</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed and/or treated at first consultation
Chart 58

**Times to First Consultation, Diagnosis and Definitive Treatment in Days by Kidney (1506 tumours)- 2003 dataset**

*Excluding tumours diagnosed before Referral*

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to first Consultation</th>
<th>Time from first consultation to Diagnosis</th>
<th>Time from Diagnosis to Definitive Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>0 *</td>
<td>289</td>
<td>19.2</td>
<td>180</td>
</tr>
<tr>
<td>1 – 14</td>
<td>679</td>
<td>45.1</td>
<td>261</td>
</tr>
<tr>
<td>15 – 28</td>
<td>254</td>
<td>16.9</td>
<td>231</td>
</tr>
<tr>
<td>29 - 60</td>
<td>174</td>
<td>11.6</td>
<td>399</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>110</td>
<td>7.3</td>
<td>435</td>
</tr>
<tr>
<td>Not Recorded</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed and/or treated at first consultation

Chart 59

**Times to First Consultation, Diagnosis and Definitive Treatment in Days by Testis (662 tumours)- 2004 dataset**

*Excluding tumours diagnosed before Referral*

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to first Consultation</th>
<th>Time from first consultation to Diagnosis</th>
<th>Time from Diagnosis to Definitive Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>0 *</td>
<td>117</td>
<td>17.7</td>
<td>84</td>
</tr>
<tr>
<td>1 – 14</td>
<td>452</td>
<td>68.3</td>
<td>386</td>
</tr>
<tr>
<td>15 – 28</td>
<td>43</td>
<td>6.5</td>
<td>118</td>
</tr>
<tr>
<td>29 - 60</td>
<td>43</td>
<td>6.5</td>
<td>118</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>29</td>
<td>4.4</td>
<td>46</td>
</tr>
<tr>
<td>Not Recorded</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed and/or treated at first consultation
Chart 60

Times to First Consultation, Diagnosis and Definitive Treatment in Days by Testis (711 tumours)- 2003 dataset
Excluding tumours diagnosed before Referral

<table>
<thead>
<tr>
<th>Days to Diagnosis</th>
<th>Time to first Consultation</th>
<th>Time from first consultation to Diagnosis</th>
<th>Time from Diagnosis to Definitive Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>0 *</td>
<td>111</td>
<td>15.6</td>
<td>88</td>
</tr>
<tr>
<td>1 – 14</td>
<td>486</td>
<td>68.4</td>
<td>403</td>
</tr>
<tr>
<td>15 – 28</td>
<td>53</td>
<td>7.5</td>
<td>123</td>
</tr>
<tr>
<td>29 - 60</td>
<td>34</td>
<td>4.8</td>
<td>59</td>
</tr>
<tr>
<td>More than 60 days</td>
<td>27</td>
<td>3.8</td>
<td>38</td>
</tr>
<tr>
<td>Not Recorded</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* = the number seen either on the day of referral or diagnosed and/or treated at first consultation
C. Histology

Histological confirmation was available in 91% of all tumours. This is 4% increase from 2003 figure and may reflect the fact that many participants use their histology departments to prompt registration of new patients. Every effort should be made to record data on patients seen in clinics and on the wards, where there is no histological diagnosis.

Chart 61

<table>
<thead>
<tr>
<th>Organ</th>
<th>Confirmation Obtained</th>
<th>%</th>
<th>Confirmation Not Obtained</th>
<th>%</th>
<th>Not Recorded</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate (14885)</td>
<td>13881</td>
<td>93.4</td>
<td>691</td>
<td>4.7</td>
<td>286</td>
<td>1.9</td>
</tr>
<tr>
<td>Bladder (6073)</td>
<td>5689</td>
<td>93.7</td>
<td>205</td>
<td>3.4</td>
<td>179</td>
<td>2.9</td>
</tr>
<tr>
<td>Kidney (2104)</td>
<td>1425</td>
<td>67.7</td>
<td>608</td>
<td>28.9</td>
<td>71</td>
<td>3.4</td>
</tr>
<tr>
<td>Testis (750)</td>
<td>685</td>
<td>91.3</td>
<td>47</td>
<td>6.3</td>
<td>18</td>
<td>2.4</td>
</tr>
<tr>
<td>Pelvis/Ureter (291)</td>
<td>235</td>
<td>80.8</td>
<td>48</td>
<td>16.5</td>
<td>8</td>
<td>2.7</td>
</tr>
<tr>
<td>Penis (196)</td>
<td>186</td>
<td>94.9</td>
<td>2</td>
<td>1.0</td>
<td>8</td>
<td>4.1</td>
</tr>
<tr>
<td>Urethra (29)</td>
<td>28</td>
<td>96.6</td>
<td>0</td>
<td>0.0</td>
<td>1</td>
<td>3.4</td>
</tr>
<tr>
<td>Prostatic Urethra (15)</td>
<td>15</td>
<td>100.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Other or Not Recorded</td>
<td>80</td>
<td>37.0</td>
<td>111</td>
<td>51.4</td>
<td>25</td>
<td>11.6</td>
</tr>
<tr>
<td>Totals (24532)</td>
<td>22224</td>
<td>90.6</td>
<td>1712</td>
<td>7.0</td>
<td>596</td>
<td>2.4</td>
</tr>
</tbody>
</table>
### Known Histology by Organ

<table>
<thead>
<tr>
<th></th>
<th>Prostate</th>
<th>Bladder</th>
<th>Kidney</th>
<th>Testis</th>
<th>Pelvis/Urinary</th>
<th>Penis</th>
<th>Urethra</th>
<th>Prostatic Urethra</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adenocarcinoma</strong></td>
<td>13502</td>
<td>95</td>
<td>137*</td>
<td>4</td>
<td>16</td>
<td>4</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>98.9%</td>
<td>1.7%</td>
<td>89.2%</td>
<td>0.6%</td>
<td>6.5%</td>
<td>2.5%</td>
<td>14.8%</td>
<td>7.1%</td>
</tr>
<tr>
<td><strong>TCC</strong></td>
<td>33</td>
<td>5441</td>
<td>153</td>
<td>2</td>
<td>226</td>
<td>4</td>
<td>18</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>0.2%</td>
<td>96.7%</td>
<td>10.2%</td>
<td>0.3%</td>
<td>92.2%</td>
<td>2.5%</td>
<td>66.7%</td>
<td>85.7%</td>
</tr>
<tr>
<td><strong>SCC</strong></td>
<td>25</td>
<td>76</td>
<td>5</td>
<td>13</td>
<td>1</td>
<td>150</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>0.2%</td>
<td>1.4%</td>
<td>0.3%</td>
<td>2.0%</td>
<td>0.4%</td>
<td>84.3%</td>
<td>18.5%</td>
<td>7.1%</td>
</tr>
<tr>
<td><strong>Mixed TCC / SCC</strong></td>
<td>-</td>
<td>17</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.3%</td>
<td>0.1%</td>
<td>0.6%</td>
<td>0.4%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Seminoma</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>373</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
<td>57.3%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Teratoma</strong></td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>173</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-</td>
<td>0.1%</td>
<td>26.6%</td>
<td>0.4%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Mixed Seminoma / Teratoma</strong></td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>82</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-</td>
<td>0.1%</td>
<td>12.6%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>High Grade PIN</strong></td>
<td>84</td>
<td>-</td>
<td>1</td>
<td>373</td>
<td>57.3%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>0.6%</td>
<td>-</td>
<td>0.1%</td>
<td>26.6%</td>
<td>0.4%</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>39</td>
<td>121</td>
<td>101</td>
<td>48</td>
<td>5</td>
<td>17</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>0.3%</td>
<td>2.1%</td>
<td>6.7%</td>
<td>7.4%</td>
<td>2.0%</td>
<td>10.7%</td>
<td>3.7%</td>
<td>7.1%</td>
</tr>
</tbody>
</table>

*N.B. Includes 1284 renal cell carcinomas*

### “Other” Histologies reported included:

<table>
<thead>
<tr>
<th></th>
<th>Prostate</th>
<th>Bladder</th>
<th>Kidney</th>
<th>Testis</th>
<th>Penis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoma in situ</td>
<td>1</td>
<td>35</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Oncocytoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarcoma/Liposarcoma / Leiomyosarcoma</td>
<td>2</td>
<td>4</td>
<td>11</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Haematological cancers</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Leydig cell</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>13</td>
</tr>
<tr>
<td>Adenocarcinoma &amp; TCC</td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sertoli</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Metastatic carcinomas</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Small cell ca/papillary renal cell / spindle cell</td>
<td>3</td>
<td>35</td>
<td>37</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Undifferentiated / anaplastic carcinoma</td>
<td>4</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Chart 64

Basis of Diagnosis when Histological Confirmation Not Obtained
(1712 tumours – 7.0% of total)

<table>
<thead>
<tr>
<th>Organ</th>
<th>Radiology</th>
<th>Cytology</th>
<th>Tumour Marker</th>
<th>Clinical</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate (691 tumours)</td>
<td>139</td>
<td>19</td>
<td>363</td>
<td>513</td>
<td>17</td>
</tr>
<tr>
<td>Bladder (205 tumours)</td>
<td>50</td>
<td>14</td>
<td>0</td>
<td>90</td>
<td>39</td>
</tr>
<tr>
<td>Kidney (608 tumours)</td>
<td>560</td>
<td>4</td>
<td>2</td>
<td>63</td>
<td>14</td>
</tr>
<tr>
<td>Testis (37 tumours)</td>
<td>32</td>
<td>0</td>
<td>2</td>
<td>13</td>
<td>2</td>
</tr>
<tr>
<td>Pelvis/Ureter (48 tumours)</td>
<td>40</td>
<td>8</td>
<td>0</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Penis (2 tumours)</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

N.B. More than one method might be used for each tumour

Chart 65

Known Differentiation by Organ
Percentage & Total of Known Differentiation

<table>
<thead>
<tr>
<th>Organ</th>
<th>Well</th>
<th>Moderate</th>
<th>Poor</th>
<th>% of Total Tumours Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Number Known)</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>Prostate (11402)</td>
<td>725</td>
<td>6.4</td>
<td>7644</td>
<td>67.0</td>
</tr>
<tr>
<td>Bladder (4493)</td>
<td>1150</td>
<td>25.6</td>
<td>1662</td>
<td>37.0</td>
</tr>
<tr>
<td>Pelvis/Ureter (78)</td>
<td>4</td>
<td>5.1</td>
<td>43</td>
<td>55.1</td>
</tr>
<tr>
<td>Penis (118)</td>
<td>45</td>
<td>38.1</td>
<td>49</td>
<td>41.5</td>
</tr>
<tr>
<td>Urethra (21)</td>
<td>3</td>
<td>14.3</td>
<td>8</td>
<td>38.1</td>
</tr>
<tr>
<td>Prostatic Urethra (10)</td>
<td>1</td>
<td>10.0</td>
<td>4</td>
<td>40.0</td>
</tr>
</tbody>
</table>

N.B. Testis and Kidney not included - RCPath minimum data set does not ask for this data which would be irrelevant to the vast majority of testicular tumours, which are mostly germ cell tumours. Kidney tumours are generally given a nuclear grade rather than a differentiation score.
D. Staging

Participants were asked to return both clinical and, where appropriate, pathological* TNM categories using the 2002 version of the TNM classification for Urological tumours which were included in the data dictionary sent to all participants.

In order to make interpretation of the resultant information easier each patient was staged, wherever possible, using the classifications as shown in the following charts. If the pathological TNM categories were given and appropriate then these were used for the staging, failing this clinical TNM categories were used.

*The pathological assessment of the primary tumour (pT) entails a “resection of the primary tumour or biopsy adequate to evaluate the highest pT category”

Less than 50% of the returns had either the full pathological TNM or clinical TNM categories and an estimate had to be made from what information was provided. (Many forms did not include any N and M categories or these were recorded as “X” – Cannot be assessed.) Whilst 65% of the returns had a relevant clinical T category (i.e. not X or null) only 31% of these had the clinical N and M categories relevantly recorded (i.e. not X or null). A plea for more accurate data recording is given and the suggestion that the BCR data may be more fully recorded if completed during the relevant Multi Disciplinary Team meeting.

The data on the following charts should therefore be regarded with caution.

The number of prostate cancers with metastases at presentation has yet again shown a small but significant decline at 95% CI whilst the number with T1c shows a significant rise at 95% CI.

Chart 66

### Staging of Kidney Tumours

A total of 2104 Kidney Tumours were reported

Staging could be estimated in 1587 (75.4%)

<table>
<thead>
<tr>
<th>Known Staging</th>
<th>Total Known</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I (T1 N0 M0)</td>
<td>594</td>
<td>37.4</td>
<td></td>
</tr>
<tr>
<td>Stage II (T2 N0 M0)</td>
<td>281</td>
<td>17.7</td>
<td></td>
</tr>
<tr>
<td>Stage III (T1, T2, T3 N0,N1 M0)</td>
<td>434</td>
<td>27.3</td>
<td></td>
</tr>
<tr>
<td>Stage IV (T4 N0,N1 M0 Any T N2 M0 Any T any N M1)</td>
<td>278</td>
<td>17.5</td>
<td></td>
</tr>
</tbody>
</table>

including 206 with metastases

13.0

N.B. A pathological staging for Kidney tumours was only included for those where radical or organ conserving surgery was performed (n =1070)
**Chart 67**

**Staging of Pelvis / Ureteric Tumours**

A total of 291 Tumours were reported

Staging could be estimated in 211 (72.5%)

<table>
<thead>
<tr>
<th>Known Staging</th>
<th>Total Known</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0a</td>
<td></td>
<td>59</td>
<td>28.0</td>
</tr>
<tr>
<td>(Ta N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 0is</td>
<td></td>
<td>1</td>
<td>0.5</td>
</tr>
<tr>
<td>(Tis N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td></td>
<td>47</td>
<td>22.3</td>
</tr>
<tr>
<td>(T1 N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage II</td>
<td></td>
<td>32</td>
<td>15.2</td>
</tr>
<tr>
<td>(T2 N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage III</td>
<td></td>
<td>42</td>
<td>19.9</td>
</tr>
<tr>
<td>(T3 N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage IV</td>
<td></td>
<td>30</td>
<td>14.2</td>
</tr>
<tr>
<td>(T4 N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any T N1, N2, N3 M0</td>
<td>including 2</td>
<td></td>
<td>0.9</td>
</tr>
<tr>
<td>Any T any N M1)</td>
<td>with metastases</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N.B. A pathological staging for Pelvis / Ureteric tumours was only included for those where radical or organ conserving surgery was performed (n =148)

---

**Chart 68**

**Staging of Bladder Tumours**

A total of 6073 Bladder Tumours were reported

Staging could be estimated in 4889 (80.5%)

<table>
<thead>
<tr>
<th>Known Staging</th>
<th>Total Known</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0a</td>
<td></td>
<td>2343</td>
<td>47.9</td>
</tr>
<tr>
<td>(Ta N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 0is</td>
<td></td>
<td>86</td>
<td>1.8</td>
</tr>
<tr>
<td>(Tis N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td></td>
<td>1339</td>
<td>27.4</td>
</tr>
<tr>
<td>(T1 N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage II</td>
<td></td>
<td>615</td>
<td>12.6</td>
</tr>
<tr>
<td>(T2a, 2b N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage III</td>
<td></td>
<td>304</td>
<td>6.2</td>
</tr>
<tr>
<td>(T3a, 3b, 4a N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage IV</td>
<td></td>
<td>202</td>
<td>4.1</td>
</tr>
<tr>
<td>(T4b N0 M0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any T N1, N2, N3 M0</td>
<td>including 69</td>
<td></td>
<td>1.4</td>
</tr>
<tr>
<td>Any T any N M1)</td>
<td>with metastases</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N.B. A pathological staging for Stage II, III or IV Bladder tumours was only included for tumours where radical surgery was performed (n =243)
Staging of Prostate Tumours

A total of 14858 Prostate Tumours were reported

Staging could be estimated in 10049 (67.6%)

<table>
<thead>
<tr>
<th>Stage</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(T1a N0 M0 Well Differentiated)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Known</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(T1a N0 M0 Mod or Poor differentiation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1b, 1c, 1, 2, N0 M0 Any differentiation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t1 –</td>
<td>535</td>
<td>5.3</td>
</tr>
<tr>
<td>t1a –</td>
<td>189</td>
<td>1.9</td>
</tr>
<tr>
<td>t1b –</td>
<td>199</td>
<td>2.0</td>
</tr>
<tr>
<td>t1c –</td>
<td>2110</td>
<td>21.4</td>
</tr>
<tr>
<td>t2 –</td>
<td>3447</td>
<td>34.3</td>
</tr>
<tr>
<td>Stage III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(T3 N0 M0 Any differentiation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage IV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(T4 N0 M0 Any differentiation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any T N1 M0 Any differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any T Any N M1 Any differentiation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>including 716 with metastases</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N.B. A pathological staging for Prostate tumours was only included for those where radical surgery was performed (n =1036).

Staging of Prostate Tumours

Comparison of clinical & pathological staging

N.B. A pathological staging for Prostate tumours was only included for those where radical surgery was performed (n =1036).

Staging could be compared in 78.9% of these (817/1036).
Chart 71

**Staging of Prostate Tumours by Age Group**

Total in Stage I where age was known = 59  
Total in Stage II where age was known = 6489  
Total in Stage III where age was known = 2199  
Total in Stage IV where age was known = 1250

Percentage of each Stage in each age group

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Stage I</th>
<th>Stage II</th>
<th>Stage III</th>
<th>Stage IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;60</td>
<td>0.4%</td>
<td>75.7%</td>
<td>15.2%</td>
<td>8.7%</td>
</tr>
<tr>
<td>60-64</td>
<td>0.3%</td>
<td>72.6%</td>
<td>18.9%</td>
<td>8.2%</td>
</tr>
<tr>
<td>65-69</td>
<td>0.4%</td>
<td>70.8%</td>
<td>19.3%</td>
<td>9.6%</td>
</tr>
<tr>
<td>70-74</td>
<td>0.8%</td>
<td>67.6%</td>
<td>20.2%</td>
<td>11.5%</td>
</tr>
<tr>
<td>75-79</td>
<td>0.7%</td>
<td>61.5%</td>
<td>24%</td>
<td>13.8%</td>
</tr>
<tr>
<td>80-84</td>
<td>1%</td>
<td>52.3%</td>
<td>28.9%</td>
<td>17.8%</td>
</tr>
<tr>
<td>85-89</td>
<td>0.2%</td>
<td>38.4%</td>
<td>36.4%</td>
<td>24.9%</td>
</tr>
<tr>
<td>&gt;=90</td>
<td>0.7%</td>
<td>33.6%</td>
<td>32.9%</td>
<td>32.9%</td>
</tr>
</tbody>
</table>

* Age could be calculated when both date of birth and diagnosis date were recorded

Chart 72

**Prostate Cancers reported 1998 - 2004**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total number reported</th>
<th>Median age at diagnosis</th>
<th>Number having T1c</th>
<th>Number having Metastases (M +ve)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998 (6 months only)</td>
<td>2909</td>
<td>74</td>
<td>250 (8.6%)</td>
<td>43 (14.9%)</td>
</tr>
<tr>
<td>1999</td>
<td>9781</td>
<td>73</td>
<td>1366 (14.0%)</td>
<td>1214 (12.4%)</td>
</tr>
<tr>
<td>2000</td>
<td>12892</td>
<td>73</td>
<td>1636 (15.8%)</td>
<td>1267/10329 (12.6%)</td>
</tr>
<tr>
<td>2001</td>
<td>15099</td>
<td>73</td>
<td>2107 (17.4%)</td>
<td>1441 / 12100 (11.9%)</td>
</tr>
<tr>
<td>2002</td>
<td>16580</td>
<td>72</td>
<td>2316 (18.3%)</td>
<td>1262 / 12645 (10.0%)</td>
</tr>
<tr>
<td>2003</td>
<td>16055</td>
<td>72</td>
<td>2156 (18.9%)</td>
<td>971/11393 (8.5%)</td>
</tr>
<tr>
<td>2004</td>
<td>14858</td>
<td>72</td>
<td>2150 (21.5%)</td>
<td>716/10049 (7.1%)</td>
</tr>
</tbody>
</table>

* Number where staging could be estimated
Chart 73

**Staging of Prostate Tumours by PSA**

Numbers falling in each category*

PSA was recorded in 84.7% tumours (12582/14858)

Gleason scores were recorded in 85.9% tumours (12756/14858)

<table>
<thead>
<tr>
<th>Known Clinical Staging</th>
<th>Total Patients</th>
<th>PSA 0-5 N %</th>
<th>PSA 6-10 N %</th>
<th>PSA 11-20 N %</th>
<th>PSA 21-50 N %</th>
<th>PSA &gt; 50 N %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I (T1a N0 M0 Well Differentiated)</td>
<td>48</td>
<td>28 58.3%</td>
<td>8 16.7%</td>
<td>7 14.6%</td>
<td>5 10.4%</td>
<td>0 0%</td>
</tr>
<tr>
<td>Stage II (T1a N0 M0 Mod or Poor differentiation T1b, 1c, 1, 2, N0 M0 Any differentiation)</td>
<td>5946</td>
<td>743 12.5%</td>
<td>2262 38.0%</td>
<td>1686 28.4%</td>
<td>854 14.4%</td>
<td>401 6.7%</td>
</tr>
<tr>
<td>Stage III (T3 N0 M0 Any differentiation)</td>
<td>1758</td>
<td>54 3.1%</td>
<td>225 12.8%</td>
<td>374 21.3%</td>
<td>506 28.8%</td>
<td>599 34.1%</td>
</tr>
<tr>
<td>Stage IV (T4 N0 M0 Any differentiation Any T N1 M0 Any differentiation Any T Any N M1 Any differentiation)</td>
<td>942</td>
<td>18 1.9%</td>
<td>42 4.5%</td>
<td>81 8.6%</td>
<td>189 20.1%</td>
<td>612 65.0%</td>
</tr>
<tr>
<td>Totals</td>
<td>8694 *</td>
<td>843 9.7%</td>
<td>2537 29.2%</td>
<td>2148 24.7%</td>
<td>1554 17.9%</td>
<td>1612 18.5%</td>
</tr>
</tbody>
</table>

N.B. Excluding pathologies other than Adenocarcinoma.

* Tumours where staging could be estimated, PSA was recorded and Histology = adenocarcinoma

Chart 74

**Gleason Sum Scores by Age Group - Prostate Tumours**

Number falling into each category

Gleason scores were recorded in 85.9% tumours (12756/14858)

Age could be recorded in 98% (12507/12756) of these

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Total Patients</th>
<th>Gleason sum 2 – 4 N %</th>
<th>Gleason sum 5 – 6 N %</th>
<th>Gleason sum 7 N %</th>
<th>Gleason sum 8 – 10 N %</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 60</td>
<td>1284</td>
<td>24 1.9</td>
<td>722 56.2</td>
<td>327 25.5</td>
<td>211 16.4</td>
</tr>
<tr>
<td>60–64</td>
<td>1644</td>
<td>25 1.5</td>
<td>871 53.0</td>
<td>482 29.3</td>
<td>266 16.2</td>
</tr>
<tr>
<td>65–69</td>
<td>2443</td>
<td>26 1.9</td>
<td>1164 47.6</td>
<td>753 30.8</td>
<td>480 19.6</td>
</tr>
<tr>
<td>70–74</td>
<td>2653</td>
<td>56 2.1</td>
<td>1134 42.7</td>
<td>831 31.3</td>
<td>632 23.8</td>
</tr>
<tr>
<td>75–79</td>
<td>2309</td>
<td>39 1.7</td>
<td>807 35.0</td>
<td>804 34.8</td>
<td>659 28.5</td>
</tr>
<tr>
<td>80–84</td>
<td>1552</td>
<td>18 1.2</td>
<td>454 29.3</td>
<td>532 34.3</td>
<td>548 35.3</td>
</tr>
<tr>
<td>85–89</td>
<td>505</td>
<td>11 2.2</td>
<td>124 24.6</td>
<td>165 32.7</td>
<td>205 40.6</td>
</tr>
<tr>
<td>&gt;=90</td>
<td>117</td>
<td>4 3.4</td>
<td>20 17.1</td>
<td>35 29.9</td>
<td>58 49.6</td>
</tr>
<tr>
<td>Totals</td>
<td>12507</td>
<td>223 1.8</td>
<td>5296 42.3</td>
<td>3929 31.4</td>
<td>3059 24.5</td>
</tr>
</tbody>
</table>
Gleason Sum Score Related to Age

Gleason scores were recorded in 85.9% tumours (12756/14858) Age could be recorded in 98% (12507/12756) of these

<table>
<thead>
<tr>
<th>Percentage of Tumours in each age group</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;60</td>
</tr>
<tr>
<td>-----</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

- **Gleason sum 2 - 4**
- **Gleason sum 5 - 6**
- **Gleason sum 7**
- **Gleason sum 8 - 10**

Staging of Testicular Tumours

A total of 750 testicular tumours were reported Staging could be estimated in 519 (69.2%)

<table>
<thead>
<tr>
<th>Known Staging</th>
<th>Seminoma</th>
<th>Teratoma</th>
<th>Combined Seminoma/Teratoma</th>
<th>Other Histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total numbers where staging &amp; histology known:</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>Stage 0 (Tis N0 M0 S0, SX)</td>
<td>1</td>
<td>0.4</td>
<td>1</td>
<td>0.8</td>
</tr>
<tr>
<td>Stage I (T1, 2, 3, 4 N0 M0 SX)</td>
<td>115</td>
<td>41.8</td>
<td>43</td>
<td>33.1</td>
</tr>
<tr>
<td>Stage IA (T1, N0 M0 S0)</td>
<td>68</td>
<td>24.7</td>
<td>13</td>
<td>10.0</td>
</tr>
<tr>
<td>Stage IB (T2, 3, 4, N0 M0 S0)</td>
<td>18</td>
<td>6.5</td>
<td>7</td>
<td>5.4</td>
</tr>
<tr>
<td>Stage IS (Any T N0 M0 S1, 2, 3)</td>
<td>63</td>
<td>22.9</td>
<td>52</td>
<td>40.0</td>
</tr>
<tr>
<td>Stage II (Any T, N1, 2, 3, M0, SX, 0, 1)</td>
<td>3</td>
<td>1.1</td>
<td>6</td>
<td>4.6</td>
</tr>
<tr>
<td>Stage III (Any T, Any N, M1, 1a, SX, 0, 1, 2, 3 Any T, N1, 2, 3, M0, S2, 3 Any T, Any N, M1b, Any S)</td>
<td>7</td>
<td>2.5</td>
<td>8</td>
<td>6.2</td>
</tr>
</tbody>
</table>
Chart 77

Testicular Tumours by Serum Tumour Marker

A total of 750 testicular tumours were reported.
Tumour markers and histology were reported in 314 (41.9%).

<table>
<thead>
<tr>
<th>Serum Tumour Marker</th>
<th>Seminoma</th>
<th>Teratoma</th>
<th>Combined Seminoma/Teratoma</th>
<th>Other Histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>S0</td>
<td>95</td>
<td>59.4</td>
<td>27</td>
<td>32.5</td>
</tr>
<tr>
<td>(Serum marker study levels within normal limits)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S1</td>
<td>50</td>
<td>31.3</td>
<td>35</td>
<td>42.2</td>
</tr>
<tr>
<td>(LDH &lt;1.5*N and HCG (ml/U/ml) &lt;5,000 and AFP (ng/ml) &lt;1,000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S2</td>
<td>7</td>
<td>4.4</td>
<td>10</td>
<td>12.0</td>
</tr>
<tr>
<td>(LDH 1.5 – 10*N or HCG (ml/U/ml) 5,000 - 50,000 or AFP (ng/ml) 1,000 – 10,000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S3</td>
<td>8</td>
<td>5.0</td>
<td>11</td>
<td>13.3</td>
</tr>
<tr>
<td>(LDH &gt;10*N or HCG (ml/U/ml) &gt;50,000 or AFP (ng/ml) &gt;10,000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N.B. N indicates the upper limit or normal for the LDH assay.

Chart 78

Staging of Penile Tumours

A total of 196 penile tumours were reported.
Staging could be estimated in 129 (65.8%).

<table>
<thead>
<tr>
<th>Known Staging</th>
<th>Total Known</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td>N</td>
</tr>
<tr>
<td>(Tis, a, N0 M0)</td>
<td>22</td>
</tr>
<tr>
<td>Stage I</td>
<td>N</td>
</tr>
<tr>
<td>(T1 N0 M0)</td>
<td>52</td>
</tr>
<tr>
<td>Stage II</td>
<td>N</td>
</tr>
<tr>
<td>(T2 N0, N1 M0)</td>
<td>31</td>
</tr>
<tr>
<td>Stage III</td>
<td>N</td>
</tr>
<tr>
<td>(T1, 2, N2 M0)</td>
<td>17</td>
</tr>
<tr>
<td>T3, N0, N1, N2, M0</td>
<td>17</td>
</tr>
<tr>
<td>Stage IV</td>
<td>N</td>
</tr>
<tr>
<td>(T4, Any N M0)</td>
<td>7</td>
</tr>
<tr>
<td>Any T N3 M0</td>
<td></td>
</tr>
<tr>
<td>Any T Any N M1</td>
<td></td>
</tr>
<tr>
<td>including 1 with metastases</td>
<td></td>
</tr>
</tbody>
</table>
E. Initial Treatment Intention and Type

Inclusion of additional categories of treatment type has made analyses more meaningful by significantly reducing the number of “other” treatments. We note that the number of laparoscopic procedures is still increasing.

Chart 79

<table>
<thead>
<tr>
<th>Organ</th>
<th>Curative</th>
<th>Palliative</th>
<th>No active anti-cancer treatment</th>
<th>% of Total Tumours Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Number Known)</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>Prostate (11615)</td>
<td>5131</td>
<td>44.2</td>
<td>4750</td>
<td>40.9</td>
</tr>
<tr>
<td>Bladder (5132)</td>
<td>4574</td>
<td>89.1</td>
<td>450</td>
<td>8.8</td>
</tr>
<tr>
<td>Kidney (1765)</td>
<td>1273</td>
<td>72.1</td>
<td>332</td>
<td>18.8</td>
</tr>
<tr>
<td>Testis (620)</td>
<td>613</td>
<td>98.9</td>
<td>6</td>
<td>1.0</td>
</tr>
<tr>
<td>Pelvis/Ureter (234)</td>
<td>189</td>
<td>80.8</td>
<td>32</td>
<td>13.7</td>
</tr>
<tr>
<td>Penis (146)</td>
<td>132</td>
<td>90.4</td>
<td>9</td>
<td>6.2</td>
</tr>
<tr>
<td>Urethra (25)</td>
<td>15</td>
<td>60.0</td>
<td>7</td>
<td>28.0</td>
</tr>
<tr>
<td>Prostatic Urethra (11)</td>
<td>7</td>
<td>63.6</td>
<td>2</td>
<td>18.2</td>
</tr>
</tbody>
</table>
Chart 80

**Treatment Intention of Prostatic Tumours by PSA and Age**

Percentage by PSA in each Age Group

- PSA <=10
- PSA 11 - 20
- PSA >20

<table>
<thead>
<tr>
<th>PSA Group</th>
<th>Curative</th>
<th>Palliative</th>
<th>No active anti-cancer treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;70</td>
<td>100%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>70-79</td>
<td>80%</td>
<td>20%</td>
<td>0%</td>
</tr>
<tr>
<td>80+</td>
<td>60%</td>
<td>40%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Chart 81

**Known Treatment Management Kidney Tumours**

Total Numbers Reported with those as only Treatment in ( )

(N.B. Excluding TCC’s)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Curative</th>
<th>Palliative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endoscopic Resection</td>
<td>5 (5)</td>
<td>1</td>
</tr>
<tr>
<td>Radical Ablative Surgery</td>
<td>879 (807)</td>
<td>100 (47)</td>
</tr>
<tr>
<td>Organ Conserving Surgery *</td>
<td>82 (76)</td>
<td>-</td>
</tr>
<tr>
<td>Biopsy &amp;/or Ultrasound guided biopsy</td>
<td>4 (2)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Other Surgery</td>
<td>12 (6)</td>
<td>7 (1)</td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td>4</td>
<td>19 (9)</td>
</tr>
<tr>
<td>Systemic Chemotherapy</td>
<td>4</td>
<td>14 (4)</td>
</tr>
<tr>
<td>Hormone Therapy</td>
<td>2</td>
<td>6 (5)</td>
</tr>
<tr>
<td>Systemic Immunotherapy</td>
<td>19 (2)</td>
<td>50 (16)</td>
</tr>
<tr>
<td>Intravesical Immunotherapy</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Palliative care</td>
<td>2</td>
<td>28 (20)</td>
</tr>
<tr>
<td>Referred to another centre / specialist</td>
<td>27 (5)</td>
<td>18 (4)</td>
</tr>
<tr>
<td>Surveillance / monitoring</td>
<td>18 (2)</td>
<td>5 (1)</td>
</tr>
<tr>
<td>Other Treatment</td>
<td>11 (1)</td>
<td>6 (2)</td>
</tr>
</tbody>
</table>

* Performed by 36 centres, median per centre = 1, Range 1 - 12
90 centres performed no organ conserving surgery
### Chart 82

**Known Treatment Management - Pelvis/Ureteric Tumours**

*Total Numbers Reported with those as only Treatment in ( )*

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Curative</th>
<th>Palliative</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surgery:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endoscopic Resection</td>
<td>6 (6)</td>
<td>-</td>
</tr>
<tr>
<td>Endoscopic Resection + 1 shot intravesical chemotherapy</td>
<td>-</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Radical Ablative Surgery</td>
<td>62 (51)</td>
<td>4 (3)</td>
</tr>
<tr>
<td>Organ Conserving Surgery</td>
<td>1 (1)</td>
<td>-</td>
</tr>
<tr>
<td>Cystoscopy</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Other Surgery</td>
<td>3 (2)</td>
<td>-</td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td>3</td>
<td>3 (1)</td>
</tr>
<tr>
<td>Systemic Chemotherapy</td>
<td>2</td>
<td>4 (3)</td>
</tr>
<tr>
<td>Referred to another centre / specialist</td>
<td>3 (2)</td>
<td>-</td>
</tr>
<tr>
<td>Intra-vesical Chemotherapy (course)</td>
<td>2 (1)</td>
<td>-</td>
</tr>
<tr>
<td>Immunotherapy</td>
<td>2</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Palliative care</td>
<td>-</td>
<td>7 (6)</td>
</tr>
<tr>
<td>Surveillance / Active Monitoring</td>
<td>2</td>
<td>-</td>
</tr>
</tbody>
</table>

### Chart 83

**Known Management by T category and Grade - Bladder Tumours**

*Total Numbers Reported with those as only Treatment in ( )*

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Tis</th>
<th>Ta G1</th>
<th>Ta G2</th>
<th>Ta G3</th>
<th>T1 G1</th>
<th>T1 G2</th>
<th>T1 G3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surgery:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endoscopic Resection</td>
<td>12 (5)</td>
<td>269 (194)</td>
<td>238 (157)</td>
<td>51 (29)</td>
<td>90 (65)</td>
<td>167 (116)</td>
<td>152 (75)</td>
</tr>
<tr>
<td>Endoscopic Resection + 1 shot intravesical chemotherapy</td>
<td>10 (4)</td>
<td>354 (292)</td>
<td>419 (363)</td>
<td>70 (44)</td>
<td>68 (61)</td>
<td>205 (156)</td>
<td>156 (92)</td>
</tr>
<tr>
<td>Radical Ablative Surgery</td>
<td>3 (1)</td>
<td>8 (5)</td>
<td>4 (3)</td>
<td>2 (2)</td>
<td>2 (1)</td>
<td>5 (2)</td>
<td>17 (9)</td>
</tr>
<tr>
<td>Organ Conserving Surgery</td>
<td>-</td>
<td>8 (1)</td>
<td>4 (2)</td>
<td>-</td>
<td>3 (1)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Biopsy / ultrasound guided biopsy</td>
<td>1</td>
<td>26 (9)</td>
<td>10 (3)</td>
<td>3 (1)</td>
<td>4</td>
<td>6</td>
<td>10 (2)</td>
</tr>
<tr>
<td>Cystoscopy</td>
<td>6</td>
<td>96 (8)</td>
<td>61 (8)</td>
<td>6</td>
<td>16 (2)</td>
<td>40 (13)</td>
<td>33 (4)</td>
</tr>
<tr>
<td>Other Surgery</td>
<td>-</td>
<td>5 (3)</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td>-</td>
<td>1</td>
<td>2</td>
<td>2 (1)</td>
<td>-</td>
<td>3 (1)</td>
<td>12</td>
</tr>
<tr>
<td>Intra-vesical Chemotherapy (course)</td>
<td>6 (2)</td>
<td>30 (2)</td>
<td>32 (4)</td>
<td>7</td>
<td>34 (4)</td>
<td>23 (2)</td>
<td></td>
</tr>
<tr>
<td>Intra-vesical Immunotherapy (course)</td>
<td>19 (8)</td>
<td>4</td>
<td>13 (1)</td>
<td>28 (1)</td>
<td>1</td>
<td>24 (1)</td>
<td>71 (1)</td>
</tr>
<tr>
<td>Surveillance / active monitoring</td>
<td>-</td>
<td>23 (2)</td>
<td>46 (3)</td>
<td>2</td>
<td>3</td>
<td>15 (2)</td>
<td>11 (1)</td>
</tr>
<tr>
<td>Referral</td>
<td>1 (1)</td>
<td>2 (1)</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>2 (1)</td>
<td>8 (1)</td>
</tr>
<tr>
<td>Other Treatment</td>
<td>-</td>
<td>4 (2)</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>1</td>
<td>3 (1)</td>
</tr>
<tr>
<td><strong>Total Tumours Reported</strong></td>
<td>86</td>
<td>919</td>
<td>886</td>
<td>158</td>
<td>127</td>
<td>523</td>
<td>453</td>
</tr>
</tbody>
</table>
Known Management by T category and Grade - Bladder Tumours where Age is \(\leq 70\) 

Total Numbers Reported with those as only Treatment in ( )

<table>
<thead>
<tr>
<th>Treatment</th>
<th>T2 G1</th>
<th>T2 G2</th>
<th>T2 G3</th>
<th>T3 G1</th>
<th>T3 G2</th>
<th>T3 G3</th>
<th>T4 G1</th>
<th>T4 G2</th>
<th>T4 G3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery: Endoscopic Resection</td>
<td>2 (1)</td>
<td>14 (5)</td>
<td>68</td>
<td>3</td>
<td>4 (2)</td>
<td>27</td>
<td>-</td>
<td>5</td>
<td>23</td>
</tr>
<tr>
<td>Endoscopic Resection + 1 shot intravesical chemotherapy</td>
<td>1 (1)</td>
<td>7 (4)</td>
<td>23 (7)</td>
<td>1 (1)</td>
<td>-</td>
<td>4 (1)</td>
<td>-</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Radical Ablative Surgery</td>
<td>2 (1)</td>
<td>10 (5)</td>
<td>59</td>
<td>2 (1)</td>
<td>11 (7)</td>
<td>35</td>
<td>1 (1)</td>
<td>1</td>
<td>31</td>
</tr>
<tr>
<td>Organ Conserving Surgery</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2 (1)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Other Surgery</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>4 (2)</td>
<td>-</td>
<td>-</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td>-</td>
<td>3 (1)</td>
<td>23 (3)</td>
<td>2</td>
<td>3</td>
<td>8 (2)</td>
<td>1</td>
<td>1</td>
<td>5 (1)</td>
</tr>
<tr>
<td>Systemic Chemotherapy</td>
<td>-</td>
<td>3</td>
<td>16 (1)</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>24 (9)</td>
</tr>
<tr>
<td>Intra-vesical Chemotherapy (course)</td>
<td>1 (1)</td>
<td>2</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Hormone Therapy</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Intra-vesical Immunotherapy (course)</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Referral</td>
<td>-</td>
<td>1</td>
<td>16</td>
<td>-</td>
<td>-</td>
<td>5</td>
<td>-</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Total Tumours Reported</td>
<td>6</td>
<td>28</td>
<td>137</td>
<td>5</td>
<td>18</td>
<td>71</td>
<td>2</td>
<td>9</td>
<td>59</td>
</tr>
</tbody>
</table>

Known Management by T category and Grade - Bladder Tumours where Age >70 

Total Numbers Reported with those as only Treatment in ( )

<table>
<thead>
<tr>
<th>Treatment</th>
<th>T2 G1</th>
<th>T2 G2</th>
<th>T2 G3</th>
<th>T3 G1</th>
<th>T3 G2</th>
<th>T3 G3</th>
<th>T4 G1</th>
<th>T4 G2</th>
<th>T4 G3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery: Endoscopic Resection</td>
<td>2 (2)</td>
<td>35</td>
<td>186</td>
<td>2</td>
<td>14</td>
<td>80</td>
<td>1 (1)</td>
<td>8</td>
<td>56</td>
</tr>
<tr>
<td>Endoscopic Resection + 1 shot intravesical chemotherapy</td>
<td>-</td>
<td>14 (8)</td>
<td>40</td>
<td>-</td>
<td>1</td>
<td>13</td>
<td>1 (1)</td>
<td>1 (1)</td>
<td>2</td>
</tr>
<tr>
<td>Radical Ablative Surgery</td>
<td>-</td>
<td>6 (3)</td>
<td>24 (9)</td>
<td>1 (1)</td>
<td>4 (3)</td>
<td>28 (15)</td>
<td>-</td>
<td>1</td>
<td>21 (12)</td>
</tr>
<tr>
<td>Organ Conserving Surgery</td>
<td>1 (1)</td>
<td>-</td>
<td>2 (1)</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cystoscopy</td>
<td>-</td>
<td>2</td>
<td>24 (1)</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>3 (1)</td>
</tr>
<tr>
<td>Other Surgery</td>
<td>-</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>1 (1)</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td>1</td>
<td>10 (1)</td>
<td>120</td>
<td>1</td>
<td>9 (2)</td>
<td>48</td>
<td>1 (1)</td>
<td>3</td>
<td>30</td>
</tr>
<tr>
<td>Systemic Chemotherapy</td>
<td>-</td>
<td>1</td>
<td>12</td>
<td>-</td>
<td>3</td>
<td>8 (1)</td>
<td>-</td>
<td>1</td>
<td>13 (2)</td>
</tr>
<tr>
<td>Intra-vesical Chemotherapy (course)</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>Hormone Therapy</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Intra-vesical Immunotherapy (course)</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Referral</td>
<td>-</td>
<td>6</td>
<td>24 (4)</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Other Treatment</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Total Tumours Reported</td>
<td>3</td>
<td>57</td>
<td>281</td>
<td>3</td>
<td>22</td>
<td>135</td>
<td>3</td>
<td>10</td>
<td>94</td>
</tr>
</tbody>
</table>
Chart 86

**Known Management Intention - Prostate Tumours**

**Total Numbers Reported with those as only Treatment in ()**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Curative</th>
<th>Palliative/ No active anti-cancer treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endoscopic Resection</td>
<td>402 (207)</td>
<td>448 (130)</td>
</tr>
<tr>
<td>Endoscopic Resection + 1 shot intravesical chemotherapy</td>
<td>10 (4)</td>
<td>4</td>
</tr>
<tr>
<td>Radical Ablative Surgery</td>
<td>1693 (1461)</td>
<td>27 (17)</td>
</tr>
<tr>
<td>Organ Conserving Surgery</td>
<td>33 (17)</td>
<td>39 (18)</td>
</tr>
<tr>
<td>Brachytherapy</td>
<td>206 (117)</td>
<td>12 (5)</td>
</tr>
<tr>
<td>Biopsy / Ultrasound guided biopsy</td>
<td>445 (72)</td>
<td>453 (40)</td>
</tr>
<tr>
<td>Other Surgery</td>
<td>11 (4)</td>
<td>4 (1)</td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td>1908 (580)</td>
<td>275 (42)</td>
</tr>
<tr>
<td>Systemic Chemotherapy / Intravesical Chemotherapy (course)</td>
<td>16 (2)</td>
<td>18 (6)</td>
</tr>
<tr>
<td>Hormone Therapy</td>
<td>1657 (321)</td>
<td>4342 (3537)</td>
</tr>
<tr>
<td>Intravesical Immunotherapy / Intravesical Immunotherapy (course)</td>
<td>2 (1)</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Watchful waiting</td>
<td>45 (11)</td>
<td>443 (339)</td>
</tr>
<tr>
<td>Surveillance / Active monitoring</td>
<td>105 (42)</td>
<td>928 (744)</td>
</tr>
<tr>
<td>Referral to another centre / specialist</td>
<td>415 (58)</td>
<td>89 (12)</td>
</tr>
<tr>
<td>Other Treatment</td>
<td>41 (16)</td>
<td>41 (16)</td>
</tr>
</tbody>
</table>

Chart 87

**Known Management by PSA - Prostate Tumours**

**where age is <= 70**

**Total Numbers Reported with those as only Treatment in ()**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>PSA 0-5</th>
<th>PSA 6-10</th>
<th>PSA 11-15</th>
<th>PSA 16-20</th>
<th>PSA 21-50</th>
<th>PSA &gt;50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endoscopic Resection</td>
<td>56 (29)</td>
<td>46 (22)</td>
<td>18 (4)</td>
<td>16 (6)</td>
<td>29 (7)</td>
<td>41 (8)</td>
</tr>
<tr>
<td>Radical Ablative Surgery</td>
<td>316 (281)</td>
<td>820 (698)</td>
<td>239 (194)</td>
<td>65 (57)</td>
<td>27 (18)</td>
<td>8 (7)</td>
</tr>
<tr>
<td>Biopsy / Ultrasound guided biopsy</td>
<td>67 (1)</td>
<td>224</td>
<td>90 (1)</td>
<td>46</td>
<td>98 (1)</td>
<td>93</td>
</tr>
<tr>
<td>Brachytherapy</td>
<td>33 (20)</td>
<td>104 (61)</td>
<td>19 (8)</td>
<td>7 (5)</td>
<td>3 (1)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Other Surgery</td>
<td>1 (1)</td>
<td>2</td>
<td>3 (3)</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td>126 (43)</td>
<td>493 (169)</td>
<td>258 (61)</td>
<td>139 (38)</td>
<td>258 (38)</td>
<td>70 (7)</td>
</tr>
<tr>
<td>Chemotherapy (systemic or intravesical course)</td>
<td>4</td>
<td>4 (3)</td>
<td>5 (1)</td>
<td>2</td>
<td>5 (1)</td>
<td>2</td>
</tr>
<tr>
<td>Hormone Therapy</td>
<td>95</td>
<td>408 (105)</td>
<td>280 (90)</td>
<td>173 (70)</td>
<td>451 (192)</td>
<td>664 (496)</td>
</tr>
<tr>
<td>Watchful waiting</td>
<td>24 (20)</td>
<td>49 (38)</td>
<td>19 (12)</td>
<td>6 (4)</td>
<td>2 (2)</td>
<td>1</td>
</tr>
<tr>
<td>Surveillance / Active monitoring</td>
<td>92 (74)</td>
<td>145 (109)</td>
<td>45 (36)</td>
<td>15 (10)</td>
<td>4 (2)</td>
<td>4 (1)</td>
</tr>
<tr>
<td>Referral to another centre / specialist</td>
<td>59 (14)</td>
<td>196 (40)</td>
<td>65 (15)</td>
<td>21 (5)</td>
<td>41 (8)</td>
<td>20 (1)</td>
</tr>
<tr>
<td>Other Treatment</td>
<td>10 (5)</td>
<td>19 (8)</td>
<td>7 (1)</td>
<td>2</td>
<td>9 (4)</td>
<td>6 (1)</td>
</tr>
</tbody>
</table>
### Chart 88

**Known Management by PSA - Prostate Tumours**  
*where age is > 70*  
**Total Numbers Reported with those as only Treatment in ( )*    

<table>
<thead>
<tr>
<th>Treatment</th>
<th>PSA 0-5</th>
<th>PSA 6-10</th>
<th>PSA 11-15</th>
<th>PSA 16-20</th>
<th>PSA 21-50</th>
<th>PSA &gt;50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endoscopic Resection</td>
<td>83 (42)</td>
<td>84 (33)</td>
<td>52 (19)</td>
<td>41 (15)</td>
<td>86 (26)</td>
<td>124 (23)</td>
</tr>
<tr>
<td>Radical Ablative Surgery</td>
<td>20 (18)</td>
<td>65 (57)</td>
<td>26 (20)</td>
<td>8 (6)</td>
<td>6 (5)</td>
<td>10 (2)</td>
</tr>
<tr>
<td>Biopsy /Ultrasound guided biopsy</td>
<td>21 (6)</td>
<td>132 (40)</td>
<td>142 (48)</td>
<td>101 (34)</td>
<td>165 (34)</td>
<td>185 (26)</td>
</tr>
<tr>
<td>Brachytherapy</td>
<td>2 (1)</td>
<td>21 (15)</td>
<td>8 (4)</td>
<td>2</td>
<td>1</td>
<td>4 (1)</td>
</tr>
<tr>
<td>Other Surgery</td>
<td>-</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td>41 (13)</td>
<td>267 (95)</td>
<td>221 (65)</td>
<td>137 (31)</td>
<td>198 (39)</td>
<td>53 (5)</td>
</tr>
<tr>
<td>Chemotherapy (systemic or intravesical course)</td>
<td>1 (1)</td>
<td>4 (1)</td>
<td>1 (1)</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Hormone Therapy</td>
<td>88 (48)</td>
<td>415 (217)</td>
<td>474 (276)</td>
<td>410 (266)</td>
<td>1079 (774)</td>
<td>1514 (1189)</td>
</tr>
<tr>
<td>Watchful waiting</td>
<td>40 (22)</td>
<td>136 (104)</td>
<td>91 (71)</td>
<td>42 (25)</td>
<td>51 (44)</td>
<td>7 (2)</td>
</tr>
<tr>
<td>Surveillance / Active monitoring</td>
<td>77 (56)</td>
<td>255 (191)</td>
<td>172 (129)</td>
<td>71 (51)</td>
<td>88 (75)</td>
<td>25 (7)</td>
</tr>
<tr>
<td>Referral to another centre / specialist</td>
<td>8</td>
<td>53 (10)</td>
<td>34 (6)</td>
<td>17 (2)</td>
<td>31 (5)</td>
<td>16 (8)</td>
</tr>
<tr>
<td>Other Treatment</td>
<td>3 (2)</td>
<td>10 (6)</td>
<td>8 (3)</td>
<td>3 (1)</td>
<td>4 (1)</td>
<td>6 (1)</td>
</tr>
</tbody>
</table>

### Chart 89

**Known Management - Testicular Tumours**  
**Total Numbers Reported with those as only Treatment in ( )*    

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Curative</th>
<th>Palliative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radical Ablative Surgery</td>
<td>567 (314)</td>
<td>4 (1)</td>
</tr>
<tr>
<td>Organ Conserving Surgery</td>
<td>2 (2)</td>
<td>-</td>
</tr>
<tr>
<td>Other Surgery</td>
<td>4 (1)</td>
<td>-</td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td>76 (7)</td>
<td>-</td>
</tr>
<tr>
<td>Systemic Chemotherapy</td>
<td>125 (3)</td>
<td>2</td>
</tr>
<tr>
<td>Intravesical Chemotherapy (course)</td>
<td>3 (1)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Surveillance/active monitoring</td>
<td>21 (1)</td>
<td>-</td>
</tr>
<tr>
<td>Referral to another centre/specialist</td>
<td>82 (3)</td>
<td>1</td>
</tr>
<tr>
<td>Other Treatment</td>
<td>6 (2)</td>
<td>-</td>
</tr>
</tbody>
</table>
Chart 90

**Known Management - Penile Tumours**

**Total Numbers Reported with those as only Treatment in ()**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Curative</th>
<th>Palliative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radical Ablative Surgery</td>
<td>35 (29)</td>
<td>3 (2)</td>
</tr>
<tr>
<td>Organ Conserving Surgery</td>
<td>72 (52)</td>
<td>2</td>
</tr>
<tr>
<td>Biopsy / US guided biopsy</td>
<td>8 (3)</td>
<td>1</td>
</tr>
<tr>
<td>Other Surgery</td>
<td>11 (3)</td>
<td>1</td>
</tr>
<tr>
<td>Radiation Therapy</td>
<td>3 (1)</td>
<td>1</td>
</tr>
<tr>
<td>Systemic Chemotherapy</td>
<td>-</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Referral to another centre/specialist</td>
<td>13 (7)</td>
<td>1</td>
</tr>
<tr>
<td>Surveillance/Active Monitoring</td>
<td>5 (3)</td>
<td>1</td>
</tr>
<tr>
<td>Other Treatment</td>
<td>-</td>
<td>1 (1)</td>
</tr>
</tbody>
</table>

Chart 91

**Laparoscopic Procedures Performed**

Number of tumours recorded as being operated on laparoscopically = 497

<table>
<thead>
<tr>
<th>Organ</th>
<th>Procedure and Number Reported</th>
<th>Organ</th>
<th>Procedure and Number Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>284 Radical prostatectomies</td>
<td>Kidney</td>
<td>141 Nephrectomy</td>
</tr>
<tr>
<td>290 total</td>
<td>2 Lymph node sampling/staging</td>
<td>169 total</td>
<td>13 Nephroureterectomy</td>
</tr>
<tr>
<td></td>
<td>1 Bilateral lymphadenectomy</td>
<td></td>
<td>7 Partial Nephrectomy</td>
</tr>
<tr>
<td></td>
<td>3 Procedure not recorded</td>
<td></td>
<td>2 Converted procedures</td>
</tr>
<tr>
<td>Bladder</td>
<td>3 Radical cystectomies</td>
<td>Pelvis/Ureter</td>
<td>31 Nephroureterectomy</td>
</tr>
<tr>
<td>4 total</td>
<td>1 Radical prostatourethrectomy &amp; ileal canal diversion</td>
<td>34 total</td>
<td>1 Nephrectomy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 Procedure not recorded</td>
</tr>
</tbody>
</table>
**Chart 92**

**Laparoscopic Surgery by Organ and Stage**

Number of tumours recorded as being operated on laparoscopically = 497

<table>
<thead>
<tr>
<th>Staging</th>
<th>Prostate N/A</th>
<th>Bladder N</th>
<th>Kidney N</th>
<th>Pelvis/Urter N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0a</td>
<td>N/A</td>
<td>1</td>
<td>N/A</td>
<td>9</td>
</tr>
<tr>
<td>Stage I</td>
<td>-</td>
<td>2</td>
<td>107</td>
<td>6</td>
</tr>
<tr>
<td>Stage II</td>
<td>247</td>
<td>1</td>
<td>14</td>
<td>5</td>
</tr>
<tr>
<td>Stage III</td>
<td>21</td>
<td>-</td>
<td>12</td>
<td>2</td>
</tr>
<tr>
<td>Stage IV</td>
<td>-</td>
<td>-</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>Not Recorded</td>
<td>22</td>
<td>-</td>
<td>32</td>
<td>12</td>
</tr>
<tr>
<td>Totals</td>
<td>290</td>
<td>4</td>
<td>169</td>
<td>34</td>
</tr>
</tbody>
</table>
F. Tertiary Referrals

We note a reduction in the percentage (6%) of tertiary referrals in 2004. This is primarily due to the large decrease in returns from one major tertiary referral centre.

Chart 93

<table>
<thead>
<tr>
<th>Organ</th>
<th>Number Recorded</th>
<th>Mean Age at Diagnosis &amp; Range</th>
<th>Males</th>
<th>Females</th>
<th>% of Total Registrations in 2003</th>
<th>% of Total Registrations in 2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>900</td>
<td>68.3; 21 - 95</td>
<td>900</td>
<td></td>
<td>6.1</td>
<td>11.4</td>
</tr>
<tr>
<td>Bladder</td>
<td>203</td>
<td>69.5; 31 - 94</td>
<td>152</td>
<td>49</td>
<td>3.3</td>
<td>5.6</td>
</tr>
<tr>
<td>Kidney</td>
<td>257</td>
<td>64.2; 20 - 98</td>
<td>160</td>
<td>97</td>
<td>12.2</td>
<td>14.2</td>
</tr>
<tr>
<td>Testis</td>
<td>28</td>
<td>39.1; 20 - 65</td>
<td>28</td>
<td></td>
<td>3.7</td>
<td>14.7</td>
</tr>
<tr>
<td>Pelvis/Ureter</td>
<td>32</td>
<td>68.4; 51 - 83</td>
<td>17</td>
<td>15</td>
<td>11.0</td>
<td>9.9</td>
</tr>
<tr>
<td>Penis</td>
<td>40</td>
<td>67.1; 40 - 88</td>
<td>40</td>
<td></td>
<td>20.4</td>
<td>13.4</td>
</tr>
<tr>
<td>Urethra</td>
<td>3</td>
<td>69.7; 64 - 73</td>
<td>1</td>
<td>2</td>
<td>10.3</td>
<td>10.0</td>
</tr>
<tr>
<td>Prostatic Urethra</td>
<td>1</td>
<td>81</td>
<td>1</td>
<td></td>
<td>6.7</td>
<td>6.7</td>
</tr>
<tr>
<td>Other</td>
<td>4</td>
<td>75.7; 66 - 82</td>
<td>3</td>
<td>1</td>
<td>13.8</td>
<td>8.2</td>
</tr>
<tr>
<td>Not recorded</td>
<td>8</td>
<td>56.7; 39 - 68</td>
<td>8</td>
<td></td>
<td>4.3</td>
<td>25.2</td>
</tr>
</tbody>
</table>

* % of the total registrations for each tumour site e.g. prostate = 900/14858 = 6.1%
** Equivalent figures recorded for diagnoses in 2002 & 2003
G. Clinical Trial Status / Delay to Diagnosis and discussion at MDT meeting

This field has continues to be poorly completed with some 42% of the returns not including the information and a further 18% where the clinical trial status was unknown. It is with regret that we note that only 2.9% of patients appeared to be eligible for clinical trials.

Delay to diagnosis and discussion at MDT meeting. These were new items for 2003 and continue to be well completed. It is pleasing to note that the number of new cancers being discussed at an MDT meeting has risen significantly at the 95% CI from 55% in 2003 to 70% in 2004.

Chart 94

### Clinical Trial Status

Status was reported in 58% of cases (14224 / 24532)

<table>
<thead>
<tr>
<th>Trial Status</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient eligible, consented to and entered trial</td>
<td>554</td>
<td>2.3</td>
</tr>
<tr>
<td>Patient eligible for trial but declined entry</td>
<td>148</td>
<td>0.6</td>
</tr>
<tr>
<td>Patient ineligible for trial</td>
<td>1231</td>
<td>5.0</td>
</tr>
<tr>
<td>Patient not considered for trial</td>
<td>7839</td>
<td>32.0</td>
</tr>
<tr>
<td>Clinical trial status unknown</td>
<td>4452</td>
<td>18.1</td>
</tr>
<tr>
<td>Not Recorded</td>
<td>10308</td>
<td>42.0</td>
</tr>
</tbody>
</table>
Chart 95

### Delay to Diagnosis

*Question completed in 88.8% of cases (21794 / 24532)*

<table>
<thead>
<tr>
<th>Delay</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>18816</td>
<td>76.7</td>
</tr>
<tr>
<td>Patient Delay</td>
<td>351</td>
<td>1.4</td>
</tr>
<tr>
<td>Radiology Delay</td>
<td>335</td>
<td>1.4</td>
</tr>
<tr>
<td>Repeat Biopsies</td>
<td>607</td>
<td>2.5</td>
</tr>
<tr>
<td>Clinical Delay</td>
<td>688</td>
<td>2.8</td>
</tr>
<tr>
<td>Administrative Delay</td>
<td>227</td>
<td>0.9</td>
</tr>
<tr>
<td>DNA (unspecified reasons)</td>
<td>77</td>
<td>0.3</td>
</tr>
<tr>
<td>Other Delay</td>
<td>693</td>
<td>2.8</td>
</tr>
<tr>
<td>Not Recorded</td>
<td>2738</td>
<td>11.2</td>
</tr>
</tbody>
</table>

Chart 96

### Was the Patient discussed at an MDT meeting with formation of a management plan?

<table>
<thead>
<tr>
<th>Response</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>17257</td>
<td>70.3</td>
</tr>
<tr>
<td>No</td>
<td>5368</td>
<td>21.9</td>
</tr>
<tr>
<td>Not Known or Not Recorded</td>
<td>1907</td>
<td>7.8</td>
</tr>
</tbody>
</table>
H. Completeness of Data

The trends are favourable. Whilst the recording of NHS number has improved significantly it still remains a problem and has implications for matching our data to that of other cancer registries and conforming to our plans for the future to retain the NHS number as the only patient identifiable item.

Chart 97

Completeness of Data -1
Percentage and numbers of Total Returns unknown

<table>
<thead>
<tr>
<th>Data Item</th>
<th>2004 Number Unknown</th>
<th>% of Total Returns 24532</th>
<th>2003 Number Unknown</th>
<th>% of Total Returns 27225</th>
<th>2002 Number Unknown</th>
<th>% of Total Returns 28351</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centre no or Cons no</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hospital number</td>
<td>**760</td>
<td>3.1</td>
<td>*993</td>
<td>3.6</td>
<td>**499</td>
<td>1.8</td>
</tr>
<tr>
<td>NHS number</td>
<td>2975</td>
<td>12.1</td>
<td>4753</td>
<td>17.5</td>
<td>8801</td>
<td>31.0</td>
</tr>
<tr>
<td>Postcode</td>
<td>948</td>
<td>3.9</td>
<td>1251</td>
<td>4.6</td>
<td>1769</td>
<td>6.2</td>
</tr>
<tr>
<td>Sex</td>
<td>113</td>
<td>4.6</td>
<td>93</td>
<td>0.3</td>
<td>78</td>
<td>0.3</td>
</tr>
<tr>
<td>Date of Birth</td>
<td>244</td>
<td>10.0</td>
<td>137</td>
<td>0.5</td>
<td>159</td>
<td>0.6</td>
</tr>
<tr>
<td>Organ</td>
<td>181</td>
<td>7.4</td>
<td>151</td>
<td>0.6</td>
<td>177</td>
<td>0.6</td>
</tr>
<tr>
<td>Date of Diagnosis</td>
<td>84</td>
<td>0.3</td>
<td>1184</td>
<td>4.3</td>
<td>551</td>
<td>1.9</td>
</tr>
<tr>
<td>Referral Source</td>
<td>1592</td>
<td>6.5</td>
<td>1694</td>
<td>6.2</td>
<td>2087</td>
<td>7.4</td>
</tr>
<tr>
<td>Priority of GP Referrals</td>
<td>776/17123</td>
<td>4.5</td>
<td>625/18610</td>
<td>3.4</td>
<td>1172/19983</td>
<td>5.9</td>
</tr>
<tr>
<td>Date of Referral</td>
<td>2419</td>
<td>9.9</td>
<td>3588</td>
<td>13.2</td>
<td>3436</td>
<td>12.1</td>
</tr>
<tr>
<td>Date of First Consultation</td>
<td>2101</td>
<td>8.6</td>
<td>2004</td>
<td>7.4</td>
<td>2286</td>
<td>8.1</td>
</tr>
<tr>
<td>Date of Definitive Treatment</td>
<td>7707</td>
<td>31.4</td>
<td>9495</td>
<td>34.9</td>
<td>10071</td>
<td>35.5</td>
</tr>
<tr>
<td>Delay to Diagnosis #</td>
<td>2738</td>
<td>11.2</td>
<td>2865</td>
<td>10.5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Histological confirmation</td>
<td>593</td>
<td>2.4</td>
<td>1836</td>
<td>6.7</td>
<td>1626</td>
<td>5.7</td>
</tr>
<tr>
<td>Basis of diagnosis if no Histology</td>
<td>175/1713</td>
<td>10.2</td>
<td>255/1724</td>
<td>14.8</td>
<td>131/1484</td>
<td>8.8</td>
</tr>
</tbody>
</table>

Includes private patients, * = 160 + 220 from 1 centre with data extraction problems; ** = 385 *** = 168 pp +552 from 2 centres with extraction problems

# New data item 2003

Chart 98

Completeness of Data -2
Percentage and numbers of Total Returns unknown

<table>
<thead>
<tr>
<th>Data Item</th>
<th>2004 Number Unknown</th>
<th>% of Total Returns 24532</th>
<th>2003 Number Unknown</th>
<th>% of Total Returns 27225</th>
<th>2002 Number Unknown</th>
<th>% of Total Returns 28351</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histology</td>
<td>787/22226</td>
<td>3.5</td>
<td>1228/23650</td>
<td>5.2</td>
<td>834/25241</td>
<td>3.3</td>
</tr>
<tr>
<td>Differentiation</td>
<td>5230/22226</td>
<td>23.5</td>
<td>5294/23650</td>
<td>22.3</td>
<td>4551/25241</td>
<td>16.1</td>
</tr>
<tr>
<td>Clinical T Category</td>
<td>2669</td>
<td>10.9</td>
<td>2715</td>
<td>10.0</td>
<td>1876</td>
<td>6.6</td>
</tr>
<tr>
<td>Clinical N Category</td>
<td>4057</td>
<td>16.5</td>
<td>4233</td>
<td>15.5</td>
<td>4430</td>
<td>15.6</td>
</tr>
<tr>
<td>Clinical M Category</td>
<td>4453</td>
<td>18.2</td>
<td>4548</td>
<td>16.7</td>
<td>3881</td>
<td>13.7</td>
</tr>
<tr>
<td>Pathological T Category*</td>
<td>1503/10343</td>
<td>14.5</td>
<td>821/5171</td>
<td>15.9</td>
<td>1228/5482</td>
<td>22.4</td>
</tr>
<tr>
<td>Pathological N Category*</td>
<td>2411/10343</td>
<td>23.3</td>
<td>966/5171</td>
<td>18.7</td>
<td>1443/5482</td>
<td>26.3</td>
</tr>
<tr>
<td>Pathological M Category*</td>
<td>2448/10343</td>
<td>23.7</td>
<td>987/5171</td>
<td>19.1</td>
<td>1477/5482</td>
<td>26.9</td>
</tr>
<tr>
<td>PSA at time of Diagnosis</td>
<td>2276/14858</td>
<td>15.3</td>
<td>2812/16055</td>
<td>17.5</td>
<td>2086/16580</td>
<td>12.6</td>
</tr>
<tr>
<td>Gleason Scores</td>
<td>2102/14858</td>
<td>14.1</td>
<td>2600/16055</td>
<td>16.2</td>
<td>2112/16580</td>
<td>7.4</td>
</tr>
<tr>
<td>S Category</td>
<td>436/750</td>
<td>58.1</td>
<td>468/910</td>
<td>51.4</td>
<td>558/9984</td>
<td>56.7</td>
</tr>
<tr>
<td>Treatment Intention</td>
<td>4949</td>
<td>20.2</td>
<td>5958</td>
<td>21.9</td>
<td>5759</td>
<td>20.3</td>
</tr>
<tr>
<td>Treatment Type</td>
<td>703/17559</td>
<td>4.0</td>
<td>720/18939</td>
<td>3.8</td>
<td>975/20133</td>
<td>4.8</td>
</tr>
<tr>
<td>Clinical Trial Status</td>
<td>10705</td>
<td>43.6</td>
<td>12218</td>
<td>44.9</td>
<td>12897</td>
<td>45.5</td>
</tr>
<tr>
<td>Discussed at MDT #</td>
<td>1907</td>
<td>7.8</td>
<td>1819</td>
<td>6.7</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pathological Ref. No. #</td>
<td>6322</td>
<td>25.8</td>
<td>10466</td>
<td>38.4</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* A pathological staging for Stage II, III or IV bladder tumours and all prostate tumours was only expected where radical surgery was performed. For kidney & pelvis/ureteric tumours it was only expected for those where radical or organ conserving surgery was performed.

# New data item 2003
Appendix – Participants over the Years

The following table displays a list of all Hospitals contributing data to the BCR during the pilot period 1st April to 30th September 1998 and the six consecutive 12 month periods from January 1999 to December 2004. The final column shows those contributing data for the complex operations dataset for the calendar year 2004. Hospitals contributing six months or less data in 2004 are marked ✓.

N.B. Not all consultants from each participating hospital have contributed data

<table>
<thead>
<tr>
<th>Hospital</th>
<th>1998</th>
<th>1999</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>Complex Ops 2004</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aberdeen Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Addenbrooke's Hospital</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Airedale General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Alexandra Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Altnagelvin Area Hospital</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Antrim Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrowe Park Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Ashford Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Ayr Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Balfour Hospital</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnet &amp; Chase Farm Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Barnsley DGH</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basildon Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Bassetlaw District General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Battle Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Bedford Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Belfast City Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Belford Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Blackburn Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Bolton Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Borders General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bradford Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Bristol Oncology Centre</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Bromley Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Bronglais Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Broomfield Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burnley General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calderdale Royal Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Castle Hill Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Central Middlesex Hospital</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cheltenham General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chesterfield &amp; North Derbyshire</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Christie Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Churchill Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City Hospital NHS Trust</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colchester General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conquest Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital</td>
<td>1998</td>
<td>1999</td>
<td>2000</td>
<td>2001</td>
<td>2002</td>
<td>2003</td>
<td>2004</td>
<td>Complex Ops 2004</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Cookridge Hospital</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>County Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Cumberland Infirmary</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darent Valley Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derby City General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Derriford Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>District General Hospital, Southport</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Doncaster Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Dorset County Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Dr Gray's Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Dumfries &amp; Galloway Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Eastbourne District Hospital</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Edith Cavell Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Epsom General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Freeman Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Frimley Park Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Furness General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Gartnavel General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>George Eliot Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Glen Clwyd Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Glasgow Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Gloucestershire Royal Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Good Hope District General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Goode &amp; District Hospital</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Grimsby DGH</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Guy's Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Hammersmith Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Harold Wood Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Harrogate District Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Heartlands &amp; Solihull NHS Trust</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Hemel Hempstead General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Hillingdon Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Homerton Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Hope Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Huddersfield Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Institute of Urology</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Inverclyde Royal Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>James Cook University Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>James Paget Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Kent and Sussex Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Kettering General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Kidderminster Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>King George Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>King's College Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>King's Mill Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Kingston Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Leicester General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Leighton Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Hospital</td>
<td>1998</td>
<td>1999</td>
<td>2000</td>
<td>2001</td>
<td>2002</td>
<td>2003</td>
<td>2004</td>
<td>Complex Ops 2004</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Lincoln &amp; Louth NHS Trust</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Lister Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Lorn Island District General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Luton &amp; Dunstable Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maidstone Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Manchester Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Mayday University Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Medway Maritime Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Mid Ulster Hospital</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Milton Keynes General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Monklands District General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Morriston Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Mount Vernon &amp; Watford Hospitals</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Nevill Hall Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>New Cross Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Ninewells Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Noble's Isle of Man Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Norfolk &amp; Norwich Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>North Devon District Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>North Hampshire Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>North Middlesex Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Northampton General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Northwick Park Hospital</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nottingham City Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Ormskirk District General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Perth Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pilgrim Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pinderfields Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Prince Philip Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Princess Alexandra Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Princess Margaret Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Princess Of Wales Hospital</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Queen Elizabeth Hospital, Birmingham</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Queen Elizabeth Hospital, Woolwich</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Queen Elizabeth Hospital, King's Lynn</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Queen Margaret Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Queen's Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Raigmore Hospital</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotherham District General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Royal Alexandra Hospital (Paisley)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Royal Bournemouth Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Royal Cornwall Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Royal Devon and Exeter Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Royal Free Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Royal Glamorgan Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Royal Gwent Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Royal Hallamshire Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Royal Hampshire County Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Hospital</td>
<td>1998</td>
<td>1999</td>
<td>2000</td>
<td>2001</td>
<td>2002</td>
<td>2003</td>
<td>2004 Complex Ops</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>Royal Lancaster Infirmary</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royal Liverpool University Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royal Orthopaedic Hospital</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royal Preston Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royal Shrewsbury Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royal Surrey County Hospital</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royal Sussex County Hospital</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royal United Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Salisbury District Hospital</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sandwell District General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scarborough Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scunthorpe General Hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Southampton General Hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Southend Hospital</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Southern General Hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Southmead Health Services Trust</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>St Bartholomew's Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>St George’s Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>St Helier Hospital</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>St James's University Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>St John’s Hospital</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>St Mary’s Hospital, Portsmouth</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>St Mary’s Hospital, IOW</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>St Mary’s Hospital, London</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>St Peter’s Hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>St Richard’s Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>St Vincents Hospital</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stafford DGH</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stepping Hill Hospital</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stirling Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Stobhill Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stoke Mandeville Hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Strathcroy Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunderland Royal Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taunton And Somerset Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>The Countess of Chester Hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>The Ipswich Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Royal Oldham Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Torbay Hospital</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ulster Hospital Dundonald</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>United Bristol Health Care Trust</td>
<td></td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University Hospital of North Durham</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University Hospital of North Stafford</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>University Hospital Of Wales</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vale of Leven Hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Walsall Manor Hospital N H S Trust</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Walsgrave Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wansbeck General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital</td>
<td>1998</td>
<td>1999</td>
<td>2000</td>
<td>2001</td>
<td>2002</td>
<td>2003</td>
<td>2004</td>
<td>Complex Ops 2004</td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Warrington District General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Warwick Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>West Suffolk Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>West Wales General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Western General Hospital, Edinburgh</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Western Isles Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Weston - Super - Mare General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Wexham Park Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Whips Cross Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Whiston Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Wigan Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Wishaw General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Worcester Royal Infirmary</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Worthing Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Wrexham Maelor Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Wycombe General Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Yeovil District Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>York District Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Ysbyty Gwynedd Hospital</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

63